var title_f41_46_42720="Mechanics hands PI";
var content_f41_46_42720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanic's hands in a patient with polymyositis, and the anti-synthetase syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42720=[""].join("\n");
var outline_f41_46_42720=null;
var title_f41_46_42721="Rash - Henoch Schonlein purpura IgA vasculitis B";
var content_f41_46_42721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Kim, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42721=[""].join("\n");
var outline_f41_46_42721=null;
var title_f41_46_42722="Patient information: Melanoma skin cancer (The Basics)";
var content_f41_46_42722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15499\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/11/41143\">",
"         Is it a mole or melanoma?",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/26/26018\">",
"         Patient information: Skin cancer (non-melanoma) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/8/39042\">",
"         Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/6/28772\">",
"         Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/30/18913\">",
"         Patient information: Sunburn (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/60/33729\">",
"         Patient information: Sunburn prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Melanoma skin cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/melanoma-skin-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H544790850\">",
"      <span class=\"h1\">",
"       What is melanoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Melanoma is a serious form of skin cancer. It happens when normal cells in the skin change into abnormal cells and grow out of control.",
"     </p>",
"     <p>",
"      Melanoma can occur anywhere on the skin, including the back and other hard-to-see areas. It can also occur on the skin lining the mouth, nose, and genitals. When it is not treated, melanoma can spread to organs inside the body. Melanoma can run in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790857\">",
"      <span class=\"h1\">",
"       What are the symptoms of melanoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Melanoma often looks like a brown or black mole or birthmark. But melanoma has features that make it different from normal moles and birthmarks. People can remember the abnormal features of melanoma by thinking of the letters A, B, C, D, and E (",
"      <a class=\"graphic graphic_picture graphicRef52518 \" href=\"mobipreview.htm?40/11/41143\">",
"       picture 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         A",
"        </strong>",
"        symmetry &ndash; One half can look different than the other half.",
"       </li>",
"       <li>",
"        <strong>",
"         B",
"        </strong>",
"        order &ndash; It can have a jagged or uneven edge.",
"       </li>",
"       <li>",
"        <strong>",
"         C",
"        </strong>",
"        olor &ndash; It can have different colors.",
"       </li>",
"       <li>",
"        <strong>",
"         D",
"        </strong>",
"        iameter &ndash; It is larger than the eraser on the end of a pencil.",
"       </li>",
"       <li>",
"        <strong>",
"         E",
"        </strong>",
"        volution &ndash; Its color or shape can change over time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Skin affected by melanoma can also bleed or become swollen, red, or crusty.",
"     </p>",
"     <p>",
"      Many moles and birthmarks are normal and are not melanoma. But if you have a mole or birthmark that you think might be abnormal, show it to your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790864\">",
"      <span class=\"h1\">",
"       Is there a test for melanoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and check the skin all over your body. If he or she suspects you have melanoma, you will have a follow-up test called a biopsy. During a biopsy, a doctor will usually remove the whole abnormal area. In some cases, the doctor might instead take a small sample of skin from the abnormal area. Either way, another doctor will look at the skin that is removed under a microscope to see if the cells have melanoma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790871\">",
"      <span class=\"h1\">",
"       What is melanoma staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Staging is a way in which doctors find out how deep in the skin and how far inside the body the melanoma has spread.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your melanoma. Your treatment will also depend on your age and other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790878\">",
"      <span class=\"h1\">",
"       How is melanoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with melanoma have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Melanoma is usually treated with surgery to remove the cancer. That&rsquo;s usually true even if the biopsy appeared to have removed the whole abnormal area. During surgery, the doctor might also check nearby lymph nodes to see if the melanoma has spread inside the body. Lymph nodes are bean-shaped organs under the skin that store infection-fighting cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Immunotherapy",
"        </strong>",
"        &ndash; Immunotherapy is the term doctors use to describe medicines that work with the body&rsquo;s infection-fighting system to stop cancer growth.",
"       </li>",
"       <li>",
"        <strong>",
"         Targeted therapy",
"        </strong>",
"        &ndash; Targeted therapy is the term doctors use to describe a group of medicines that work only on cancers with certain characteristics. These medicines usually work by blocking a specific protein or molecule.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790885\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will need to be checked every so often to see if the melanoma comes back or if new melanomas appear. Your doctor will do an exam and check your skin all over. He or she might also order follow up blood tests or imaging tests. Imaging tests create images of the inside of your body and can show abnormal growths.",
"     </p>",
"     <p>",
"      Most doctors also recommend that you check your skin every month to look for any changes. Tell your doctor or nurse if you find any new moles or birthmarks, or if the ones you have look different.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790892\">",
"      <span class=\"h1\">",
"       What happens if the melanoma comes back or if a new melanoma appears?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the melanoma comes back or if you develop a new melanoma, you might have more surgery, radiation therapy, chemotherapy, or immunotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790899\">",
"      <span class=\"h1\">",
"       Can melanoma be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help prevent melanoma by protecting your skin from the sun&rsquo;s rays. Sun exposure and sunburn are a big cause of melanoma. To reduce the chance of getting melanoma, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stay out of the sun in the middle of the day (from 10 a.m. to 4 p.m.)",
"       </li>",
"       <li>",
"        Wear sunscreen and reapply it often",
"       </li>",
"       <li>",
"        Wear a wide-brimmed hat, long-sleeved shirt, or long pants",
"       </li>",
"       <li>",
"        Not use tanning beds. They increase your risk of getting melanoma",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790906\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544790913\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/26/26018?source=see_link\">",
"       Patient information: Skin cancer (non-melanoma) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"       Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=see_link\">",
"       Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=see_link\">",
"       Patient information: Sunburn prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/30/18913?source=see_link\">",
"       Patient information: Sunburn (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/46/42722?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15499 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42722=[""].join("\n");
var outline_f41_46_42722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790850\">",
"      What is melanoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790857\">",
"      What are the symptoms of melanoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790864\">",
"      Is there a test for melanoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790871\">",
"      What is melanoma staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790878\">",
"      How is melanoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790885\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790892\">",
"      What happens if the melanoma comes back or if a new melanoma appears?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790899\">",
"      Can melanoma be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790906\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544790913\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/11/41143\">",
"      Is it a mole or melanoma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_46_42723="Visual analog scale";
var content_f41_46_42723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Visual analog scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Visual Analog Scale (VAS) (10 cm line).",
"    <br>",
"     [Score = 0 - 100 mm] - measuring in millimeters from the left hand end of the line to the point that the patient marks.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42723=[""].join("\n");
var outline_f41_46_42723=null;
var title_f41_46_42724="MAP kinase pathway";
var content_f41_46_42724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitogen-activated protein (MAP) kinase pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 633px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RTK: receptor tyrosine kinase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42724=[""].join("\n");
var outline_f41_46_42724=null;
var title_f41_46_42725="Erythrasma in axilla";
var content_f41_46_42725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 24-year-old male presented with erythematous plaques in the axillae. A Wood's lamp examination was positive for coral red fluorescence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42725=[""].join("\n");
var outline_f41_46_42725=null;
var title_f41_46_42726="Hematogenous osteomyelitis in adults";
var content_f41_46_42726=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematogenous osteomyelitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Jason Calhoun, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Mark E Shirtliff, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42726/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/46/42726/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous osteomyelitis accounts for approximately 20 percent of cases of osteomyelitis in adults. It occurs more frequently in males. Hematogenous osteomyelitis most commonly involves the vertebral bones; the next most common sites are the flat bones of the axial skeleton, such as the clavicle and pelvis. Less frequently, the long bones of the appendicular skeleton can be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematogenous osteomyelitis in adults will be reviewed here. Hematogenous osteomyelitis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link\">",
"     \"Treatment of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous osteomyelitis is primarily a disease of children, with 85 percent of cases occurring in patients younger than 17 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/2\">",
"     2",
"    </a>",
"    ]. The proportion of adult cases may be increasing as the mean age of the population rises in the United States and developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases in adults are observed in patients over age 50, with the exception of intravenous drug users, the majority of whom are under age 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/4\">",
"     4",
"    </a>",
"    ]. Hematogenous osteomyelitis is also associated with other risk factors for bacteremia (eg, central lines, dialysis, sickle cell disease, urethral catheterization, urinary tract infection).",
"   </p>",
"   <p>",
"    The site of infection varies with age. In children, the most common sites of involvement are the long bones (eg, femur, tibia, and humerus); vertebral osteomyelitis accounting for only 1 to 2 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/5\">",
"     5",
"    </a>",
"    ]. In adults the long bones are rarely involved; the major sites of infection are the vertebrae and the sternoclavicular and pelvic bones (the latter two most commonly occurring in intravenous drug users) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=see_link\">",
"     \"Pelvic osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among adult patients with hematogenous infection of the hip, magnetic resonance imaging has demonstrated that infection commonly extends distal to the femoral head, into the medullary canal of the femur or acetabulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with vertebral osteomyelitis, the lumbar vertebral bodies are most often involved, followed in frequency by the thoracic and cervical vertebrae. Spread to adjacent vertebral bodies may occur rapidly through the rich venous networks in the spine. Posterior extension may lead to epidural and subdural abscesses or even meningitis. Extension anteriorly or laterally can lead to paravertebral, retropharyngeal, mediastinal, subphrenic, retroperitoneal, or psoas abscesses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of infection in hematogenous osteomyelitis in children is thought to be due to specific features of long bone anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of long bone hematogenous osteomyelitis in adults, infection usually begins in the diaphysis but may spread to involve the entire medullary canal. Extension into the epiphysis and joint space can occur, since the growth plate has matured and shares vessels with the metaphysis. Since the periosteum is firmly adherent to the bone, cortical penetration usually leads to a soft tissue abscess. Subperiosteal abscesses and massive cortical devitalization occur rarely. Sinus tracts connecting the sequestered nidus of infection to the skin can develop over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of bacterial deposition in the metaphysis is unclear. Examination of the capillary loops of the metaphyseal vessels by electron microscopy has shown that the distal vessels are composed of a single layer of discontinuous endothelium through which tracer particles can escape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. It is possible that bacteria also pass through these gaps during an episode bacteremia, thereby initiating osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the metaphyseal capillaries lack phagocytic lining cells, and the sinusoidal veins contain functionally inactive phagocytic cells, both of which allow growth of microorganisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any form of end-capillary obstruction, including a small hematoma as the result of minor trauma, can produce an area of avascular necrosis that is predisposed to infection.",
"   </p>",
"   <p>",
"    The pathogenesis of vertebral osteomyelitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacterial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of hematogenous osteomyelitis depends upon the ability of specific bacteria to bind to host tissue. Staphylococcus aureus can adhere to tissue by binding host proteins, including fibronectin, fibrinogen, and collagen, which may well account for the predominance of S. aureus in hematogenous osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39269?source=see_link\">",
"     \"Pathogenesis of osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of binding to collagen for the development of osteomyelitis was illustrated in a murine model of acute hematogenous osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/15\">",
"     15",
"    </a>",
"    ]. Mice infected with a S. aureus collagen-binding adhesin (cna) mutant were less likely to develop osteomyelitis compared to mice infected with a S. aureus strain wild type for this gene (1 of 20 [5 percent] infected with the cna mutant compared to 14 of 20 [70 percent] the wild type strain). These adhesion factors may account for the predominance of S. aureus in bone infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous osteomyelitis occurs after a bacteremia, although the bacteremia is not apparent in every case. Hematogenous osteomyelitis is usually monomicrobial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/8,16-18\">",
"     8,16-18",
"    </a>",
"    ]. S. aureus is the most commonly isolated organism. Aerobic gram-negative rods are identified in 30 percent of cases. Salmonella osteomyelitis is well described among patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/19\">",
"     19",
"    </a>",
"    ]. Pseudomonas aeruginosa and Serratia marcescens are observed more frequently among intravenous drug users than other patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of unusual pathogens have also been reported, especially in vertebral osteomyelitis, including Candida species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], Bartonella henselae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/24\">",
"     24",
"    </a>",
"    ], Coccidioides immitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], and Propionibacterium acnes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local symptoms referable to bones are frequently absent. Soft tissue findings may be more prominent than signs of bony involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults with vertebral osteomyelitis usually present with vague symptoms and signs consisting of dull, constant back pain and spasm of the paravertebral muscles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among adults with hematogenous long bone osteomyelitis, clinical symptoms resulting from soft tissue extension and involvement of the hip and piriformis muscle can be prominent, leading to inappropriate diagnostic and therapeutic measures unless there is clinical suspicion for osteomyelitis.",
"   </p>",
"   <p>",
"    Multifocal involvement is most common in intravenous drug users and patients with S. aureus bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Brodie's abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brodie's abscess is a type of subacute osteomyelitis most commonly involving the distal tibia in patients younger than 25 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/28\">",
"     28",
"    </a>",
"    ]. It is usually of hematogenous origin but can also occur in the setting of trauma.",
"   </p>",
"   <p>",
"    Patients typically present with the insidious onset of mild to moderate pain, with or without periosteal elevation or fever. If the subacute process progresses to chronic localized bone abscess, patients present with longstanding dull pain in the absence of fever. Manifestations may mimic other conditions (including tumor) given the absence of acute symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/29\">",
"     29",
"    </a>",
"    ]. Radiography typically demonstrates a single lesion near the metaphysis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87102 \" href=\"mobipreview.htm?35/54/36709\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Management should include surgical debridement with antibiotic therapy tailored to culture findings. The most common pathogen is S. aureus, although other gram-positive and gram-negative organisms may be seen, and cultures may be sterile in up to one-half of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of osteomyelitis in patients with sickle cell disease can be similar to symptoms of vasoocclusive crisis (VOC). In general, infectious episodes are more likely to be associated with temperature &gt;102&ordm;F (38.9&ordm;C), persistent pain, and decreased range of motion in the case of joint involvement. Symptoms associated with both VOC and osteomyelitis include local warmth, tenderness, and swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hematogenous osteomyelitis requires a high index of clinical suspicion. Routine laboratory tests are frequently nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The earliest radiographic findings are soft tissue swelling, periosteal thickening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevation, and focal osteopenia. Destructive changes in bone lag at least two weeks behind infection; approximately 50 to 75 percent of the bone matrix must be destroyed before radiographs demonstrate lytic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/32\">",
"     32",
"    </a>",
"    ]. Subperiosteal collections, myositis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pyomyositis contiguous to a region of osteomyelitis are most readily detected by MRI.",
"   </p>",
"   <p>",
"    Distinguishing osteomyelitis from bone tumor can be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The penumbra sign, a thin layer of granulation tissue lining a bone abscess cavity, may be seen in osteomyelitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56913 \" href=\"mobipreview.htm?31/26/32161\">",
"     image 2",
"    </a>",
"    ). This finding produces a higher signal on T1 weighted MR images; in one study it had a sensitivity and specificity of 73 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of positive blood cultures together with radiographic findings consistent with osteomyelitis, a bone biopsy or subperiosteal abscess aspirate for culture is needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal diagnostic approach in patients with sickle cell disease is uncertain. Plain films, MRI, and bone scintigraphy can demonstrate positive findings in vasoocclusive crisis (VOC) as well as osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/4,24-27\">",
"     4,24-27",
"    </a>",
"    ]. A biopsy may not definitively rule out a vasoocclusive crisis, especially if no infectious agent is found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/31\">",
"     31",
"    </a>",
"    ]. Both VOC and bony infection typically demonstrate an infiltrate of neutrophils and macrophages as well as necrotic tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;After cultures are obtained, empiric antibiotics should be initiated to cover S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/1,35,36\">",
"     1,35,36",
"    </a>",
"    ]. Reasonable empiric regimens include:",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"      nafcillin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"      oxacillin",
"     </a>",
"    </span>",
"    (2 g every four hours),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (2 gm every eight hours) or, in regions where the prevalence of methicillin resistant S. aureus (MRSA) is high (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"mobipreview.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours in two equally divided doses). Once the etiologic organism is identified, the antibiotic regimen should be modified, if needed, based upon susceptibility patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with sickle cell anemia empiric therapy should cover S. aureus as well as Salmonella and other gram-negative bacilli. In intravenous drug users, empiric treatment should cover both S. aureus and gram-negative bacilli. Reasonable empiric treatment for both groups consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (750 mg orally or 400 mg intravenously every 12 hours) or other fluoroquinolone, in addition to coverage outlined above for S. aureus.",
"   </p>",
"   <p>",
"    Hematogenous osteomyelitis in adults is frequently refractory to therapy, particularly if it involves bones outside the spine and if debridement is not performed or if it is incomplete. The optimal duration of therapy is uncertain. For patients with hematogenous (nonvertebral) osteomyelitis, at least four weeks of parenteral antimicrobial therapy from the initiation of therapy or the last major debridement surgery are warranted.",
"   </p>",
"   <p>",
"    Management of vertebral osteomyelitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hematogenous osteomyelitis the nidus of infection is usually within the medullary canal of the bone. Surgical intervention is warranted if there is evidence of a persistent soft tissue abscess or subperiosteal collection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if concomitant joint infection is suspected or diagnosed. Surgical debridement is often both diagnostic and therapeutic, particularly in patients who have negative blood cultures at the time the diagnosis is suspected.",
"   </p>",
"   <p>",
"    In adults with hematogenous osteomyelitis, a thorough intramedullary reaming and unroofing is usually performed, with or without bone grafting. Debridement of necrotic bone is often necessary in patients with sternoclavicular and pubic osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42726/abstract/38\">",
"     38",
"    </a>",
"    ]. Soft tissues are reapproximated and the limb is protected by external means (brace or cast) until the structural integrity of the bone is reestablished by normal remodeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18562114\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematogenous osteomyelitis accounts for approximately 20 percent of cases of osteomyelitis in adults. It most commonly involves the vertebral bones; the next most common sites are the flat bones of the axial skeleton, such as the clavicle and pelvis. Less frequently, the long bones of the appendicular skeleton can be involved. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematogenous osteomyelitis is primarily a disease of children. Most cases in adults are observed in patients over age 50 (with the exception of intravenous drug users, the majority of whom are under age 40). Hematogenous osteomyelitis is also associated with other risk factors for bacteremia (eg, central lines, dialysis, sickle cell disease, urethral catheterization, urinary tract infection). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematogenous osteomyelitis occurs after a bacteremia, although the bacteremia is not always apparent. Hematogenous osteomyelitis is usually monomicrobial. S. aureus is the most commonly isolated organism. Aerobic gram-negative rods are identified in 30 percent of cases. Salmonella osteomyelitis is well described among patients with sickle cell disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among adults with hematogenous long bone osteomyelitis, clinical symptoms resulting from soft tissue extension and involvement of the hip and piriformis muscle can be prominent, leading to inappropriate diagnostic and therapeutic measures unless there is high index of clinical suspicion for osteomyelitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The earliest radiographic findings are soft tissue swelling, periosteal thickening",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevation, and focal osteopenia. Destructive changes in bone lag at least two weeks behind infection. In the absence of positive blood cultures together with radiographic findings consistent with osteomyelitis, a bone biopsy or subperiosteal abscess aspirate for culture is needed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After cultures are obtained, empiric antibiotics should be initiated to cover S. aureus. In patients with sickle cell anemia empiric therapy should cover also cover Salmonella and other gram-negative bacilli. In intravenous drug users, empiric treatment should cover both S. aureus and gram-negative bacilli. The optimal duration of therapy is uncertain; at least four weeks of parenteral antimicrobial therapy from the initiation of therapy or the last major debridement surgery are warranted. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention is warranted if there is evidence of a persistent soft tissue abscess or subperiosteal collection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if concomitant joint infection is suspected or diagnosed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/1\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/2\">",
"      Mader JT, Shirtliff M, Calhoun JH. The host and the skeletal infection: classification and pathogenesis of acute bacterial bone and joint sepsis. Baillieres Best Pract Res Clin Rheumatol 1999; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/3\">",
"      Espersen F, Frimodt-M&oslash;ller N, Thamdrup Rosdahl V, et al. Changing pattern of bone and joint infections due to Staphylococcus aureus: study of cases of bacteremia in Denmark, 1959-1988. Rev Infect Dis 1991; 13:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/4\">",
"      Chandrasekar PH, Narula AP. Bone and joint infections in intravenous drug abusers. Rev Infect Dis 1986; 8:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/5\">",
"      Fernandez M, Carrol CL, Baker CJ. Discitis and vertebral osteomyelitis in children: an 18-year review. Pediatrics 2000; 105:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/6\">",
"      Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med 2005; 353:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/7\">",
"      Zalavras CG, Rigopoulos N, Lee J, et al. Magnetic resonance imaging findings in hematogenous osteomyelitis of the hip in adults. Clin Orthop Relat Res 2009; 467:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/8\">",
"      Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 1970; 282:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/9\">",
"      Calhoun JH, Manring MM, Shirtliff M. Osteomyelitis of the long bones. Semin Plast Surg 2009; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/10\">",
"      Ham KN, Hurley JV, Ryan GB, Storey E. Localization of particulate carbon in metaphyseal vessels of growing rats. Aust J Exp Biol Med Sci 1965; 43:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/11\">",
"      Anderson CE, Parker J. Invasion and resorption in enchondral ossification. An electron microscopic study. J Bone Joint Surg Am 1966; 48:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/12\">",
"      Emslie KR, Nade S. Pathogenesis and treatment of acute hematogenous osteomyelitis: evaluation of current views with reference to an animal model. Rev Infect Dis 1986; 8:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/13\">",
"      Hobo, T. Zur pathogenese de akuten haematatogenen Osteomyelitis, mit Beruckishtigun der Vitalfarbungslehre. Acta Sch Med Univ Imp Kioto 1922; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/14\">",
"      Patti JM, Allen BL, McGavin MJ, H&ouml;&ouml;k M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994; 48:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/15\">",
"      Elasri MO, Thomas JR, Skinner RA, et al. Staphylococcus aureus collagen adhesin contributes to the pathogenesis of osteomyelitis. Bone 2002; 30:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/16\">",
"      Mader JT, Ortiz M, Calhoun JH. Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 1996; 13:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/17\">",
"      Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts). N Engl J Med 1970; 282:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/18\">",
"      Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med 1970; 282:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/19\">",
"      Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics 1998; 101:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/20\">",
"      Holzman RS, Bishko F. Osteomyelitis in heroin addicts. Ann Intern Med 1971; 75:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/21\">",
"      Garbino J, Schnyder I, Lew D, et al. An unusual cause of vertebral osteomyelitis: Candida species. Scand J Infect Dis 2003; 35:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/22\">",
"      Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis 2001; 33:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/23\">",
"      Hendrickx L, Van Wijngaerden E, Samson I, Peetermans WE. Candidal vertebral osteomyelitis: report of 6 patients, and a review. Clin Infect Dis 2001; 32:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/24\">",
"      Rolain JM, Chanet V, Laurichesse H, et al. Cat scratch disease with lymphadenitis, vertebral osteomyelitis, and spleen abscesses. Ann N Y Acad Sci 2003; 990:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/25\">",
"      Caraway NP, Fanning CV, Stewart JM, et al. Coccidioidomycosis osteomyelitis masquerading as a bone tumor. A report of 2 cases. Acta Cytol 2003; 47:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/26\">",
"      Holley K, Muldoon M, Tasker S. Coccidioides immitis osteomyelitis: a case series review. Orthopedics 2002; 25:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/27\">",
"      Do TT, Strub WM, Witte D. Subacute Propionibacterium acnes osteomyelitis of the spine in an adolescent. J Pediatr Orthop B 2003; 12:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/28\">",
"      Miller WB Jr, Murphy WA, Gilula LA. Brodie abscess: reappraisal. Radiology 1979; 132:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/29\">",
"      Gould CF, Ly JQ, Lattin GE Jr, et al. Bone tumor mimics: avoiding misdiagnosis. Curr Probl Diagn Radiol 2007; 36:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/30\">",
"      Unkila-Kallio L, Kallio MJ, Eskola J, Peltola H. Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics 1994; 93:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/31\">",
"      Ibia EO, Imoisili M, Pikis A. Group A beta-hemolytic streptococcal osteomyelitis in children. Pediatrics 2003; 112:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/32\">",
"      Butt WP. The radiology of infection. Clin Orthop Relat Res 1973; :20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/33\">",
"      Shimose S, Sugita T, Kubo T, et al. Differential diagnosis between osteomyelitis and bone tumors. Acta Radiol 2008; 49:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/34\">",
"      Seybold U, Talati NJ, Kizilbash Q, et al. Hematogenous osteomyelitis mimicking osteosarcoma due to Community Associated Methicillin-Resistant Staphylococcus aureus. Infection 2007; 35:190.",
"     </a>",
"    </li>",
"    <li>",
"     Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1322.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/36\">",
"      Cierny, G, Mader, JT. Adult chronic osteomyelitis. Orthopedics 1984; 7:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/37\">",
"      Ericsson HM, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol 1971; 217:Suppl 217:1+.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42726/abstract/38\">",
"      Sexton DJ, Heskestad L, Lambeth WR, et al. Postoperative pubic osteomyelitis misdiagnosed as osteitis pubis: report of four cases and review. Clin Infect Dis 1993; 17:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7673 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42726=[""].join("\n");
var outline_f41_46_42726=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18562114\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacterial factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Brodie's abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18562114\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7673|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/54/36709\" title=\"diagnostic image 1\">",
"      Brodie abscess radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/26/32161\" title=\"diagnostic image 2\">",
"      Penumbra sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/9/5275\" title=\"table 1\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39269?source=related_link\">",
"      Pathogenesis of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=related_link\">",
"      Pelvic osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_46_42727="Causes of chronic pancreatitis in children and adolescents";
var content_f41_46_42727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of chronic pancreatitis in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     Mohamad Miqdady, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     Seiji Kitagawa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42727/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/46/42727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis is a progressive inflammatory disease of the pancreas. It is characterized by structural changes that result in irreversible exocrine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The structural changes include diffuse or focal destruction, sclerosis, acinar cell loss, islet cell loss, inflammatory cell filtrate, and pancreatic duct abnormalities. Intraductal obstruction may be caused by protein-plugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calculi.",
"   </p>",
"   <p>",
"    Because the pancreas has a large reserve capacity, symptoms of pancreatic failure do not develop until there is loss of over 90 percent of pancreatic exocrine function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/4\">",
"     4",
"    </a>",
"    ]. Most patients with chronic pancreatitis initially experience recurrent abdominal pain, which may progress to persistent pain. Less commonly, patients are asymptomatic or have minimal symptoms until developing signs of advanced disease, such as diabetes mellitus or fat and protein malabsorption. With advances in diagnostic methods, the diagnosis of chronic pancreatitis is becoming more common in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of pathologic processes can cause chronic pancreatitis in children. However, no specific etiology can be identified for many cases, termed &ldquo;idiopathic chronic pancreatitis.&rdquo; Hereditary pancreatitis is a form of chronic pancreatitis that often presents during childhood and adolescence; it will be discussed briefly here and in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=see_link\">",
"     \"Hereditary pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following issues are discussed in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations and diagnosis of chronic pancreatitis in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of endoscopic retrograde cholangiopancreatography in the diagnosis and management of pancreatic disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24088?source=see_link\">",
"       \"ERCP for pancreatic disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The complications and treatment of chronic pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=see_link\">",
"       \"Complications of chronic pancreatitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"       \"Treatment of chronic pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CATEGORIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of schemes have been used to classify chronic pancreatitis. These schemes can be divided into two major categories: mechanistic and phenotypic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanistic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIGARO classification groups pancreatitis into categories based upon the type of pathophysiology (",
"    <a class=\"graphic graphic_table graphicRef65173 \" href=\"mobipreview.htm?33/2/33835\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Toxic/metabolic",
"      </span>",
"     </li>",
"     <li>",
"      Idiopathic",
"     </li>",
"     <li>",
"      Genetic",
"     </li>",
"     <li>",
"      Autoimmune",
"     </li>",
"     <li>",
"      Recurrent acute",
"     </li>",
"     <li>",
"      Obstructive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These classes are listed roughly in order of their prevalence in adults, and each class has implications for potential treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/5\">",
"     5",
"    </a>",
"    ]. In children, obstructive and genetic causes predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phenotypic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis can be categorized by morphology, into calcific or noncalcific phenotypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In calcific pancreatitis, the pancreatic ducts often show severe epithelial atrophy and stricturing and contain inspissated material with protein and calculi. Causes of chronic calcific pancreatitis in children include cystic fibrosis (particularly in pancreatic-sufficient patients), metabolic disorders (such as hypercalcemia and hyperlipidemia), and hereditary pancreatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/7\">",
"       7",
"      </a>",
"      ]. In adults, calcific pancreatitis is usually associated with alcohol abuse in developed countries and tropical pancreatitis in developing countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tropical pancreatitis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A noncalcific phenotype is seen in most obstructive causes of pancreatitis. These include congenital anomalies, trauma, idiopathic fibrosing pancreatitis, and sclerosing pancreatocholangitis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Obstructive'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TOXIC/METABOLIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of toxins can cause or contribute to chronic pancreatitis. Alcohol is the most common cause of chronic pancreatitis in adults, and the possibility of alcohol abuse also should be considered in adolescents presenting with recurrent pancreatitis. Tobacco smoking also is an independent and dose-dependent risk factor for chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\", section on 'Alcohol abuse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\", section on 'Cigarette smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreatitis has been observed in approximately 1 to 2 percent of adult patients after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], and this association also has been reported in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/11\">",
"     11",
"    </a>",
"    ]. The etiology is uncertain but may be related to immunosuppressive",
"    <span class=\"nowrap\">",
"     therapy/drug",
"    </span>",
"    toxicity, viral infection, or metabolic derangements associated with renal failure.",
"   </p>",
"   <p>",
"    Numerous metabolic disorders causing recurrent pancreatitis (including hypercalcemia, organic acidemia, and hyperlipidemia) also have been described in association with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Toxic or metabolic factors may interact with genetic abnormalities such as those described below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Genetic'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IDIOPATHIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a thorough evaluation fails to identify a cause of chronic pancreatitis, the disorder is considered idiopathic. A substantial number of cases of chronic pancreatitis fall into this category (30 to 70 percent in pediatric series, depending in part on which other causes are excluded) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. However, further elucidation of gene mutations associated with chronic pancreatitis may reduce the number of patients whose chronic pancreatitis is described as idiopathic. As an example, SPINK1 mutations were discovered in about 25 percent of children and adolescents previously considered to have idiopathic chronic pancreatitis, perhaps acting as a disease modifier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. PRSS1 mutations, which are typically seen in autosomal dominant hereditary pancreatitis, have also been identified in patients with idiopathic pancreatitis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Genetic'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early versus late onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who develop idiopathic chronic pancreatitis appear to have a more aggressive disease than those diagnosed in adulthood. In a retrospective study of 66 patients with idiopathic pancreatitis, the 25 patients with early-onset disease (mean age 19 years) tended to present with pain, pancreatic calcification, and often had pancreatic insufficiency; in contrast, the 41 patients diagnosed in adulthood typically had mild symptoms and a frequently painless course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tropical pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tropical pancreatitis is a condition of unknown etiology that is seen frequently in south India and other parts of the tropics where it is the most common cause of chronic pancreatitis. Affected patients often die in early adulthood from endocrine and exocrine dysfunction. The histologic changes in the pancreas are similar to those of alcoholic pancreatitis, with fatty infiltration and often calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tropical pancreatitis is strongly associated with malnutrition, but malnutrition is probably not the sole initiating factor. The cassava tuber (yuca) was initially implicated as an etiologic factor but is no longer thought to be related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/18\">",
"     18",
"    </a>",
"    ]. Mutations in the serine protease inhibitor SPINK1, which have been associated with other types of chronic pancreatitis, have been identified in some patients with tropical pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Genetic'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENETIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in genes encoding pancreatic proteins can cause inherited forms of chronic pancreatitis or modify the risk for developing chronic pancreatitis. Chronic pancreatitis has been associated with mutations in the genes encoding cationic trypsinogen (serine protease 1, or PRSS1), serine protease inhibitor Kazal type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), and chymotrypsinogen C (CTRC). One study estimated that 80 percent of children with chronic pancreatitis have a mutation in one of these genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PRSS1",
"      </strong>",
"      &ndash; Mutations in the cationic trypsinogen (serine protease 1) gene, called PRSS1, are present in up to 80 percent of cases of autosomal dominant hereditary pancreatitis. The pathogenesis of this disorder is discussed in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=see_link&amp;anchor=H3#H3\">",
"       \"Hereditary pancreatitis\", section on 'PRSS1'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Mutations in PRSS1 may also be important in some patients with presumed idiopathic pancreatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/22,23\">",
"       22,23",
"      </a>",
"      ] and in patients with acute pancreatitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Idiopathic'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link&amp;anchor=H9#H9\">",
"       \"Etiology and pathogenesis of chronic pancreatitis in adults\", section on 'Idiopathic pancreatitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44774?source=see_link&amp;anchor=H242656594#H242656594\">",
"       \"Pathogenesis of acute pancreatitis\", section on 'Genetic mutations in hereditary pancreatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       SPINK1",
"      </strong>",
"      &ndash; Mutations in",
"      <strong>",
"       s",
"      </strong>",
"      erine",
"      <strong>",
"       p",
"      </strong>",
"      rotease",
"      <strong>",
"       in",
"      </strong>",
"      hibitor",
"      <strong>",
"       K",
"      </strong>",
"      azal type",
"      <strong>",
"       1",
"      </strong>",
"      (SPINK1, also called pancreatic secretory trypsin inhibitor gene) are associated with chronic pancreatitis. They also occur in the general population (2 percent of healthy individuals carry a \"high risk\" mutation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/24\">",
"       24",
"      </a>",
"      ], but less than 1 percent of carriers develop pancreatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/15\">",
"       15",
"      </a>",
"      ]. Thus, these mutations probably act as a disease modifier, lowering the threshold for pancreatitis from other genetic or environmental factors. The majority of patients with SPINK1 mutations and chronic pancreatitis are heterozygotes, and display complex multigenerational inheritance patterns. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=see_link&amp;anchor=H16023350#H16023350\">",
"       \"Hereditary pancreatitis\", section on 'SPINK1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       CFTR",
"      </strong>",
"      &ndash; Mutations in CFTR can cause pancreatitis with or without associated manifestations of cystic fibrosis. The prevalence of chronic pancreatitis is only slightly increased in individuals who are heterozygous for a CFTR mutation as compared with the general population. Thus, the development of chronic pancreatitis in these mutation carriers probably requires additional genetic or environmental disease modifiers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=see_link&amp;anchor=H16024358#H16024358\">",
"       \"Hereditary pancreatitis\", section on 'CFTR'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chymotrypsinogen C",
"      </strong>",
"      &ndash; Chymotrypsinogen C (CTRC) is an enzyme which protects the pancreas by eliminating prematurely activated trypsin. Mutations in the CTRC gene are more common among patients with chronic pancreatitis (12 percent) as compared with the general population (1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hereditary pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis that occurs in an autosomal dominant pattern of inheritance has been termed \"hereditary pancreatitis.\" Most affected individuals have mutations in the PRSS1 gene. This disorder is discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=see_link\">",
"     \"Hereditary pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of hereditary pancreatitis is based upon the clinical history, radiographic testing in the appropriate clinical setting, and recognition of the autosomal dominant inheritance pattern. A listing of laboratories that provide genetic testing for PRSS1 mutations is available on the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/318887?db=genetests\">",
"     GeneTests website",
"    </a>",
"    . As compared with other causes of chronic pancreatitis, patients with hereditary pancreatitis often present at a young age. The majority of affected individuals develop symptoms before the age of 20 years, typically at age 10 to 12 years, but often before the age of five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/26\">",
"     26",
"    </a>",
"    ]. The most common presentation is severe acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings can suggest chronicity but cannot differentiate hereditary from other forms of chronic pancreatitis. The radiologic evaluation of hereditary and other forms of chronic pancreatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in children\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of hereditary pancreatitis is similar to that of other causes of chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Autoimmune pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune pancreatitis (AIP) is rarely reported in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/31-33\">",
"     31-33",
"    </a>",
"    ] but is increasingly recognized in adult populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/34\">",
"     34",
"    </a>",
"    ]. Older terms that described the same disease include sclerosing pancreatitis, lymphoplasmacytic sclerosing pancreatitis, and sclerosing pancreatocholangitis. AIP is categorized into two types (type 1 and type 2) with distinct clinical profiles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIP can occur as a primary pancreatic disorder or as part of multiorgan autoimmune disorders. It is usually characterized by relatively mild symptoms, with an enlarged pancreas on abdominal imaging studies, often with obstructive jaundice. The pancreatic duct usually is irregularly narrowed, although a variety of morphologies have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with type 1 AIP usually have elevated serum levels of gammaglobulin (especially IgG4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/36\">",
"     36",
"    </a>",
"    ]. Making the diagnosis is important because patients with AIP usually respond to corticosteroid therapy when treated early in the course of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40168?source=see_link&amp;anchor=H13#H13\">",
"     \"Autoimmune pancreatitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 2 autoimmune pancreatitis is seen in association with other diseases of presumed autoimmune etiology including sclerosing cholangitis, primary biliary cirrhosis, and Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/37\">",
"     37",
"    </a>",
"    ]. Acute and chronic pancreatitis have been described in children with inflammatory bowel disease (either Crohn disease or ulcerative colitis) and may precede the diagnosis of the bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. A common feature of these reports is the presence of colonic disease. In the setting of these diseases, the pathogenesis of the pancreatitis probably is multifactorial, including side effects of medications, but an autoimmune mechanism is also possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECURRENT ACUTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is not a clear distinction between diseases that cause recurrent attacks of acute pancreatitis and severe acute pancreatitis, and those causing chronic pancreatitis. As an example, patients with pancreas divisum, sphincter of Oddi dysfunction, and mutations in PRSS1 may be associated with either recurrent acute or chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, this category is a phenotypic description rather than a disease classification. Patients with severe acute pancreatitis with widespread necrosis often are left with scarring and duct destruction that becomes a chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OBSTRUCTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive (non-calcific) chronic pancreatitis occurs after obstruction of the pancreatic duct by a congenital anomaly, injury, or mass lesions. As examples, diseases that affect the proximal intestine, including Crohn disease, celiac disease, or eosinophilic gastroenteropathy, may cause chronic pancreatitis because of inflammation and obstruction of the ampulla. The parenchyma of the pancreas is characterized by diffuse or focal infiltration or replacement by fibrotic tissue, as in chronic fibrosing pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive chronic pancreatitis occurs in a minority of patients with pancreas divisum (a condition in which the head and body of the pancreas are separate glands). It also has been described in association with biliary cysts (choledochal cysts), duplications of the pancreatic duct, stomach, or duodenum, and renal cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Evaluation of these anomalies using endoscopic retrograde cholangiopancreatography is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24088?source=see_link&amp;anchor=H3#H3\">",
"     \"ERCP for pancreatic disease in children\", section on 'Congenital anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic injury from trauma usually is acute and self-limited. However, chronic pancreatitis caused by disruption of the pancreatic ducts has been described, manifested by focal chronic changes, and stricturing, compression, and obstruction of the pancreatic duct. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24088?source=see_link&amp;anchor=H14#H14\">",
"     \"ERCP for pancreatic disease in children\", section on 'Pancreatic trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Idiopathic fibrosing pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic fibrosing pancreatitis is a rare cause of chronic pancreatitis and obstructive jaundice that has been described in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The pathogenesis is unknown. Imaging findings often resemble a mass in the pancreatic head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/52\">",
"     52",
"    </a>",
"    ]. Unlike most other forms of chronic pancreatitis in children, fibrosing pancreatitis is characterized by extrinsic compression of the distal common bile duct with resulting biliary obstruction, jaundice, and abdominal pain. Many patients develop marked exocrine pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/53\">",
"     53",
"    </a>",
"    ]. The diagnosis can be established by endoscopic ultrasound (EUS), magnetic resonance cholangiopancreatography (MRCP), or ERCP; the biliary obstruction has been successfully managed by placements of stents during ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42727/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21663063\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pancreatitis can be caused by a variety of pathophysiologic mechanisms, captured in the mnemonic TIGARO",
"      <span class=\"nowrap\">",
"       (Toxic/metabolic,",
"      </span>",
"      Idiopathic, Genetic, Autoimmune, Recurrent acute, and Obstructive) (",
"      <a class=\"graphic graphic_table graphicRef65173 \" href=\"mobipreview.htm?33/2/33835\">",
"       table 1",
"      </a>",
"      ). In children, obstructive and genetic causes predominate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanistic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic pancreatitis also can be grouped by phenotype into calcific or non-calcific types. Obstructive causes usually have a non-calcific phenotype. These include congenital anomalies, trauma, idiopathic fibrosing pancreatitis, and sclerosing pancreatocholangitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Phenotypic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol is the most common cause of chronic pancreatitis in adults, and the possibility of alcohol abuse also should be considered in adolescents presenting with recurrent pancreatitis. Other",
"      <span class=\"nowrap\">",
"       toxic/metabolic",
"      </span>",
"      causes of chronic pancreatitis include hypercalcemia and hyperlipidemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Toxic/metabolic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a thorough evaluation fails to identify a cause of chronic pancreatitis, the disorder is considered idiopathic. Children who develop idiopathic chronic pancreatitis often have a more aggressive course than adults; they present with pain, pancreatic calcification, and often have pancreatic insufficiency. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Early versus late onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic causes of chronic pancreatitis included mutations in the genes encoding cationic trypsinogen (serine protease 1, or PRSS1), serine protease inhibitor Kazal type 1 (SPINK1), and cystic fibrosis transmembrane conductance regulator (CFTR). PRSS1 mutations are the most common cause of autosomal dominant hereditary pancreatitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Genetic'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=see_link\">",
"       \"Hereditary pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune pancreatitis is far more common in adults than children and is sometimes associated with a multiorgan autoimmune disorder. It is characterized by relatively mild pancreatic symptoms and elevated serum levels of gammaglobulin (especially IgG4). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Autoimmune pancreatitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40168?source=see_link\">",
"       \"Autoimmune pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is not a clear distinction between diseases that cause recurrent attacks of acute pancreatitis and severe acute pancreatitis, and those causing chronic pancreatitis. Patients with pancreas divisum, sphincter of Oddi dysfunction, and mutations in PRSS1 may be associated with either recurrent acute or chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Recurrent acute'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive (non-calcific) chronic pancreatitis occurs after obstruction of the pancreatic duct by a congenital anomaly, traumatic injury, or mass lesions. Endoscopic retrograde cholangiopancreatography (ERCP) is a valuable tool for diagnosis and sometimes for treatment. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Obstructive'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24088?source=see_link\">",
"       \"ERCP for pancreatic disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic fibrosing pancreatitis is a rare cause of chronic pancreatitis characterized by extrinsic compression of the distal common bile duct with resulting biliary obstruction, jaundice, and abdominal pain. Imaging findings often resemble a mass in the pancreatic head. The biliary obstruction has been successfully managed by placements of stents during ERCP. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Idiopathic fibrosing pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Owyang C. Chronic pancreatitis. In: Textbook of Gastroenterology, 4th, Yamada T (Ed), Lippincott, Williams and Wilkins, Philadelphia 2003. p.2061.",
"    </li>",
"    <li>",
"     Sarner M. Pancreatitis definition and classification. In: The Pancreas: Pathology and Disease, 2nd, Go VL, DiMagno EP, Gardner JD, Lebenthal E, et al (Eds), Raven, New York 1993. p.575.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/3\">",
"      Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med 1995; 332:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/4\">",
"      Gaskin KJ, Durie PR, Lee L, et al. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhea secondary to relative colipase deficiency. Gastroenterology 1984; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/5\">",
"      Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/6\">",
"      Clifton MS, Pelayo JC, Cortes RA, et al. Surgical treatment of childhood recurrent pancreatitis. J Pediatr Surg 2007; 42:1203.",
"     </a>",
"    </li>",
"    <li>",
"     Whitcomb DC, Lowe ME. Pancreatitis: Acute and chronic. In: Walker's Pediatric Gastrointestinal Disease, Kleinman RE, Sanderson IR, Goulet O-J, et al (Eds), BC Decker, Inc., Ontario 2008. Vol 2, p.1213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/8\">",
"      Mehta DI. Acute and chronic pancreatitis in childhood. Indian J Pediatr 1999; 66:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/9\">",
"      Slakey DP, Johnson CP, Cziperle DJ, et al. Management of severe pancreatitis in renal transplant recipients. Ann Surg 1997; 225:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/10\">",
"      Corrodi P, Knoblauch M, Binswanger U, et al. Pancreatitis after renal transplantation. Gut 1975; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/11\">",
"      Cho MH, Hong EH, Lee HS, Ko CW. Recurrent pancreatitis after renal transplantation in a child. Pediatr Transplant 2008; 12:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/12\">",
"      Mathew P, Wyllie R, Caulfield M, et al. Chronic pancreatitis in late childhood and adolescence. Clin Pediatr (Phila) 1994; 33:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/13\">",
"      Wang W, Liao Z, Li ZS, et al. Chronic pancreatitis in Chinese children: etiology, clinical presentation and imaging diagnosis. J Gastroenterol Hepatol 2009; 24:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/14\">",
"      Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/15\">",
"      Pf&uuml;tzer RH, Barmada MM, Brunskill AP, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/16\">",
"      Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994; 107:1481.",
"     </a>",
"    </li>",
"    <li>",
"     Pitchumoni CS, Mohan V.. Juvenile tropical pancreatitis. In: Pediatric Gastrointestinal Disease, 4 E, Walker WA, Goulet O, Kleinman RE, et al..  (Eds), BC Decker, Ontario 2004. Vol 2, p.1598-1605.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/18\">",
"      Sarles H, Augustine P, Laugier R, et al. Pancreatic lesions and modifications of pancreatic juice in tropical chronic pancreatitis (tropical calcific diabetes). Dig Dis Sci 1994; 39:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/19\">",
"      Bhatia E, Choudhuri G, Sikora SS, et al. Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology 2002; 123:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/20\">",
"      Schneider A, Suman A, Rossi L, et al. SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh. Gastroenterology 2002; 123:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/21\">",
"      Sultan M, Werlin S, Venkatasubramani N. Genetic prevalence and characteristics in children with recurrent pancreatitis. J Pediatr Gastroenterol Nutr 2012; 54:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/22\">",
"      Creighton J, Lyall R, Wilson DI, et al. Mutations of the cationic trypsinogen gene in patients with chronic pancreatitis. Lancet 1999; 354:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/23\">",
"      Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology 1999; 117:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/24\">",
"      Fink EN, Kant JA, Whitcomb DC. Genetic counseling for nonsyndromic pancreatitis. Gastroenterol Clin North Am 2007; 36:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/25\">",
"      Masson E, Chen JM, Scotet V, et al. Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. Hum Genet 2008; 123:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/26\">",
"      Keim V, Bauer N, Teich N, et al. Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene. Am J Med 2001; 111:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/27\">",
"      Sossenheimer MJ, Aston CE, Preston RA, et al. Clinical characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest Multicenter Pancreatic Study Group (MMPSG). Am J Gastroenterol 1997; 92:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/28\">",
"      Whitcomb DC. Genetic predispositions to acute and chronic pancreatitis. Med Clin North Am 2000; 84:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/29\">",
"      Sibert JR. Hereditary pancreatitis in England and Wales. J Med Genet 1978; 15:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/30\">",
"      Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/31\">",
"      Gargouri L, Ponsot P, Viala J, et al. Recurrent autoimmune pancreatitis in a 10-year-old boy. J Pediatr Gastroenterol Nutr 2009; 48:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/32\">",
"      Fukumori K, Shakado S, Miyahara T, et al. Atypical manifestations of pancreatitis with autoimmune phenomenon in an adolescent female. Intern Med 2005; 44:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/33\">",
"      Ectors N, Maillet B, Aerts R, et al. Non-alcoholic duct destructive chronic pancreatitis. Gut 1997; 41:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/34\">",
"      Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005; 5:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/35\">",
"      Okazaki K, Uchida K, Matsushita M, Takaoka M. Autoimmune pancreatitis. Intern Med 2005; 44:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/36\">",
"      Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/37\">",
"      Okazaki K, Chiba T. Autoimmune related pancreatitis. Gut 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/38\">",
"      Meltzer SJ, Korelitz BI. Pancreatitis and duodenopancreatic reflux in Crohn's disease. Case report and review of the literature. J Clin Gastroenterol 1988; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/39\">",
"      Newman LH, Wellinger JR, Present DH, Aufses AH Jr. Crohn's disease of the duodenum associated with pancreatitis: a case report and review of the literature. Mt Sinai J Med 1987; 54:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/40\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1994. An 11-year-old boy with recurrent abdominal pain and evidence of pancreatitis. N Engl J Med 1994; 330:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/41\">",
"      Broide E, Dotan I, Weiss B, et al. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr 2011; 52:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/42\">",
"      Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997; 113:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/43\">",
"      Lewin-Smith MR, Dipalma JS, Hoy GR, et al. Chronic fibrosing pancreatitis in childhood: report of a case and literature review. Pediatr Pathol Lab Med 1996; 16:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/44\">",
"      Elitsur Y, Siddiqui SY, Sloven D, et al. Chronic pancreatitis with diffuse fibrosis in early childhood. Pancreas 1989; 4:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/45\">",
"      Kamelmaz I, Elitsur Y. Pancreas divisum--the role of ERCP in children. W V Med J 1999; 95:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/46\">",
"      Guelrud M, Morera C, Rodriguez M, et al. Normal and anomalous pancreaticobiliary union in children and adolescents. Gastrointest Endosc 1999; 50:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/47\">",
"      Koc-Ku J. [Contemporary opinions on the etiology of chronic pancreatitis]. Wiad Lek 1999; 52:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/48\">",
"      Kamisawa T, Egawa N, Tsuruta K, et al. Pancreatitis associated with congenital abnormalities of the pancreaticobiliary system. Hepatogastroenterology 2005; 52:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/49\">",
"      Amerson JL, Ricketts RR. Idiopathic fibrosing pancreatitis: a rare cause of obstructive jaundice in children. Am Surg 1996; 62:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/50\">",
"      Meneely RL, O'Neill J, Ghishan FK. Fibrosing pancreatitis--an obscure causes of painless obstructive jaundice: a case report and review of the literature. Pediatrics 1981; 67:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/51\">",
"      Harb R, Naon H. Idiopathic fibrosing pancreatitis in a 3-year-old girl: a case report and review of the literature. J Pediatr Surg 2005; 40:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/52\">",
"      Buxbaum JL, Eloubeidi MA, Varadarajulu S. Utility of EUS-guided FNA in the management of children with idiopathic fibrosing pancreatitis. J Pediatr Gastroenterol Nutr 2011; 52:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/53\">",
"      Sylvester FA, Shuckett B, Cutz E, et al. Management of fibrosing pancreatitis in children presenting with obstructive jaundice. Gut 1998; 43:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42727/abstract/54\">",
"      El-Matary W, Casson D, Hodges S, et al. Successful conservative management of idiopathic fibrosing pancreatitis in children. Eur J Pediatr 2006; 165:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5895 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42727=[""].join("\n");
var outline_f41_46_42727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21663063\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CATEGORIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanistic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phenotypic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TOXIC/METABOLIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IDIOPATHIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early versus late onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tropical pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENETIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hereditary pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AUTOIMMUNE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECURRENT ACUTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OBSTRUCTIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Idiopathic fibrosing pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21663063\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/2/33835\" title=\"table 1\">",
"      TIGARO classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24088?source=related_link\">",
"      ERCP for pancreatic disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=related_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37288?source=related_link\">",
"      Hereditary pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44774?source=related_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_46_42728="Genital Chlamydia trachomatis infections in women";
var content_f41_46_42728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genital Chlamydia trachomatis infections in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42728/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42728/contributors\">",
"     Jonathan M Zenilman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42728/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42728/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42728/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42728/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/46/42728/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia trachomatis is the most common bacterial agent of sexually transmitted genital infections. A significant proportion of patients are asymptomatic, thereby providing an ongoing reservoir for infection. In infants born to mothers through an infected birth canal, conjunctivitis and pneumonia can occur.",
"   </p>",
"   <p>",
"    The microbiology, pathophysiology, epidemiology and clinical genital C. trachomatis infections in women will be reviewed here. Pelvic inflammatory disease, lymphogranuloma venereum, genital chlamydia infections in men, and endemic trachoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8409?source=see_link\">",
"     \"Epidemiology, diagnosis, and management of trachoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. trachomatis is a small gram-negative bacterium with unique biologic properties that distinguish it from all other living organisms. It is an obligate intracellular parasite that has a distinct life-cycle that consists of two major phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The small elementary bodies attach and penetrate into cells, changing into the metabolically active form, called the reticulate body, within six to eight hours (",
"      <a class=\"graphic graphic_picture graphicRef79945 \" href=\"mobipreview.htm?38/55/39798\">",
"       picture 1",
"      </a>",
"      ). These forms create large inclusions within cells.",
"     </li>",
"     <li>",
"      The reticulate bodies then reorganize into small elementary bodies, and within two to three days the cell ruptures, releasing newly formed elementary bodies. Release of the elementary bodies initiates the replicative process, since this is the form which can infect new epithelial cells. The long growth cycle explains why prolonged courses of treatment are necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chlamydia cannot be cultured on artificial media; traditionally tissue culture has been required to establish a diagnosis. Rapid and inexpensive screening tests are now available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One critical feature of chlamydial organisms is that immunity to infection is not long-lived. As a result, reinfection or persistent infection is common.",
"   </p>",
"   <p>",
"    These syndromes are caused by the C. trachomatis serovars B and D through K. The L serovars cause lymphogranuloma venereum, a genital ulcer syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental work on the pathogenesis of and immunity to C. trachomatis infection has yielded confusing and often contradictory results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/1\">",
"     1",
"    </a>",
"    ]. The cell walls of chlamydia are very similar to those of Gram negative bacteria. Thirty to 60 percent of the weight of the outer membrane of chlamydia is composed of the major outer membrane protein (MOMP). Several studies have indicated that variable portions of this protein are highly conserved but may not be the immunodominant moiety in the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In one report, vaccination of mice with plasmids containing the gene for MOMP invoked a modest immune response but did not protect against vaginal shedding of the organism or improve mouse fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/4\">",
"     4",
"    </a>",
"    ]. MOMP does appear to serve as an adhesin for binding to epithelial cells, perhaps through heparan sulfate receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other surface moieties have also been studied including lipopolysaccharide (LPS) and several heat shock proteins (Hsp). The structure of at least one LPS from C. trachomatis has been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/6\">",
"     6",
"    </a>",
"    ], and LPS appears to be important in triggering cytokine release which, in turn, provokes an inflammatory response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/7\">",
"     7",
"    </a>",
"    ]. One study determined that persistence of MOMP and LPS antigens for four weeks in vitro, even after antibiotic administration at sufficient doses to kill the organisms within cells, led to ongoing neutrophil chemotaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucosal infection induces a local inflammatory response which is characterized by lymphocytes and mononuclear cells. This can be especially demonstrated in chlamydia cervicitis where lymphocytic infiltration of adjacent cervical tissues is well-documented in cervical and endometrial biopsy specimens. Cytokine release by the lymphocytes produces additional inflammation.",
"   </p>",
"   <p>",
"    Interferon (IFN)-gamma and intercellular adhesion molecule (ICAM)-1 both appear to play a role in control of C. trachomatis infection. In one study IFN-gamma receptor knockout mice were not able to control C. trachomatis genital infection compared to animals with normal IFN-gamma receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/9\">",
"     9",
"    </a>",
"    ]. In a second study ICAM-1 knockout and control mice were both able to clear primary C. trachomatis infection although the severity of initial infection was greater in the ICAM-1 deficient animals, which were unable to rapidly activate Th1 cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of controversial questions have arisen about the immune response to C. trachomatis, including whether or not effective immunity develops and whether reinfection or response to the organism actually triggers ongoing inflammation. Data are conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study antibodies to heat shock proteins and LPS from C. trachomatis were elevated in women with tubal factor infertility and not in age-matched pregnant controls; the same findings were not replicated for antibodies to C. pneumoniae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other experiments have shown that different subtypes of monoclonal antibodies raised to MOMP of C. trachomatis can either neutralize or increase the infectivity of the organism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to Hsp10, but not Hsp60 or MOMP, were present in higher levels in women with tubal factor infertility in one series than in women acutely infected with C. trachomatis or uninfected controls, and the degree of the serologic response correlated with severity of the infertility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      in a murine model of genital infection eliminated the organism and prevented hydrosalpinx but also greatly diminished the development of an antibody response, suggesting that antibody might be protective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/14\">",
"       14",
"      </a>",
"      ]. Mice that were untreated or treated 10 days following infection had a significant rise in IgG antibodies compared to animals treated at the time of infection who had no detectable antibody response. Mice given doxycycline at three and seven days after infection had measurable IgG but at a far lower titer than the untreated animals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 4,000,000 cases of C. trachomatis infection are estimated to occur annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], making this the most common sexually transmitted disease (STD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/18\">",
"     18",
"    </a>",
"    ]. C. trachomatis and Neisseria gonorrhoeae cause similar clinical syndromes, but chlamydia infections tend to have fewer acute manifestations and more significant long-term complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of chlamydia are highest in adolescent women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/16\">",
"     16",
"    </a>",
"    ]. In one prospective study of a cohort of 14,322 individuals between the ages of 18 and 26 years, the prevalence of chlamydial infection was 4.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/19\">",
"     19",
"    </a>",
"    ]. The highest rates were in African American women (14 percent) and overall were higher in women than men. Some authorities believe that a decline in prevalence with age may be related to the development of partial immunity to clinical infection through periodic repeated exposures as well as to changes in behavior.",
"   </p>",
"   <p>",
"    A number of artifacts in the reporting scheme probably influence the published figures on the epidemiology of chlamydia infections (",
"    <a class=\"graphic graphic_figure graphicRef55053 \" href=\"mobipreview.htm?25/40/26253\">",
"     figure 1",
"    </a>",
"    ). In 1996, 490,080 cases were reported to the Centers for Disease Control and Prevention (CDC), which continued a trend of increasing incidence of chlamydia infection in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/20\">",
"     20",
"    </a>",
"    ]. However, both increased screening activity and increased reporting contributed to this trend. Reporting of chlamydia infection was required in fewer than 10 states in 1985 compared to approximately 40 states in later years. Thus, the true prevalence of chlamydia infection is not known, which presents major problems in evaluating trends.",
"   </p>",
"   <p>",
"    Most data currently come from limited cross-sectional prevalence studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One large study of United States female army military recruits found a chlamydial prevalence of 9 percent with some evidence of regional variation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chlamydia infection was diagnosed in 2.3 percent of 1149 women seen at a university health service in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/22\">",
"       22",
"      </a>",
"      ], in 16 percent of female adolescents in a middle school clinic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/23\">",
"       23",
"      </a>",
"      ], and in 5.4 percent in an urban family planning clinic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of a sample of households in the United States conducted from 1999 to 2002 as a part of the National Health and Nutrition Examination Survey (NHANES), the prevalence of chlamydia was 2.2 percent in participants ranging in age from 14 to 39 years; this corresponded to 2,291,000 prevalent infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/25\">",
"       25",
"      </a>",
"      ]. The overall prevalence was similar between men and women.",
"     </li>",
"     <li>",
"      In reports from other parts of the world, the prevalence ranges from 28.5 percent among female sex workers in Dakar [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/26\">",
"       26",
"      </a>",
"      ], to 5.7 percent among pregnant women in Thailand [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/27\">",
"       27",
"      </a>",
"      ], and 0.8 percent overall among women seen in private gynecology practices in Paris and 5.2 percent for those under the age of 21 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/28\">",
"       28",
"      </a>",
"      ]. A population based study in China estimated the prevalence of chlamydial infection at a surprisingly high rate of 2.6 per 100 population for women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While reported chlamydia infections are more common in women than in men and rates of infection have increased substantially since 1984, these figures represent artifacts of reporting. As an example, the large rate difference between women and men is due to different ascertainment practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/20\">",
"     20",
"    </a>",
"    ]. Chlamydia screening is frequently performed in women even in the absence of symptoms. By contrast, men are often treated for chlamydia without a definitive diagnosis, based upon a clinical diagnosis of urethritis or as a contact of a woman with a chlamydia infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following risk factors for developing C. trachomatis infection have been identified in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/21,22,31-33\">",
"     21,22,31-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adolescents and young adults",
"     </li>",
"     <li>",
"      Multiple sex partners or a partner with other partners during the last three months or a recent new sex partner",
"     </li>",
"     <li>",
"      Inconsistent use of barrier contraceptives",
"     </li>",
"     <li>",
"      Clinical evidence of mucopurulent cervicitis",
"     </li>",
"     <li>",
"      Cervical ectopy",
"     </li>",
"     <li>",
"      Unmarried status",
"     </li>",
"     <li>",
"      History of prior sexually transmitted disease",
"     </li>",
"     <li>",
"      Lower socioeconomic class or education not beyond high school",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age is the strongest predictor of chlamydial infection; adolescents and young adults are at highest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The prevalence of infection among sexually active adolescents is 5 to 10 percent. The high risk in young women is probably due to behavioral characteristics, as well as physiologic factors; increased exposure of cervical columnar epithelium in young woman may enhance the ability of the organism to infect new cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Marital status is another important risk factor in women. In a study of 1800 women ages 15 to 34, for example, the prevalence of infection among married, divorced, and single women was 1, 3 to 4, and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/35\">",
"     35",
"    </a>",
"    ]. Cervical ectopy, black race, douching, nulliparity, age 24 years or less, and intercourse with two or more partners within the preceding year were other risk factors identified in this report.",
"   </p>",
"   <p>",
"    The rate of transmission after exposure was addressed in a report of female sexual partners of men with urethritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/36\">",
"     36",
"    </a>",
"    ]. Among 31 partners of men with C. trachomatis alone, infection occurred in 20 (65 percent). The rate of transmission was not affected by the number of exposures or coinfection with gonorrhea. Pregnancy may predispose to infection with C. trachomatis via physiologic immunosuppression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cervical ectopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic disease is common and models employing risk factors miss one-third of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/23,38\">",
"     23,38",
"    </a>",
"    ]. A large study of high-risk adolescents in Baltimore, for example, found that the incidence of chlamydial infection was 17 percent per year, but no single risk factor was predictive of which patients were infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased transmission of HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question has arisen about whether C. trachomatis or other STDs are co-factors in the acquisition of HIV infection. Several prospective assessments of women during seroconversion to HIV have documented an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In a nested case control study, 431 HIV-negative female sex workers from Zaire were followed over a two-year period; the incidence of HIV infection was 9.8 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/39\">",
"     39",
"    </a>",
"    ]. The odds ratio for seroconversion after adjusting for sexual exposures among those with chlamydia infection was 3.6 and 4.8 for gonorrhea. A smaller study from Thailand also documented an adjusted risk ratio of 3.3 for cervical C. trachomatis infection and seroconversion to HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the natural history of genital chlamydia infections are sparse. Knowledge of the rates of spontaneous resolution, persistence, and progression of untreated chlamydial infections may influence treatment recommendations.",
"   </p>",
"   <p>",
"    Researchers prospectively evaluated the natural history of chlamydial infection in 129 patients during the interval between screening and follow-up for a positive chlamydia test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eighty-nine percent of the participants were female; the median interval between screening and treatment was 13 days. Resolution (as assayed by nucleic acid amplification techniques) occurred in 18 percent. Persistent infection was associated with clinical symptoms of cervicitis and urethritis at follow-up; two women developed complications related to infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6322940\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of symptomatic disease ranges from 7 to 14 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of women with C. trachomatis infection are asymptomatic, clinical manifestations range from cervicitis to pelvic inflammatory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cervicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, cervical infection is the most common chlamydial syndrome (",
"    <a class=\"graphic graphic_picture graphicRef67848 \" href=\"mobipreview.htm?35/17/36114\">",
"     picture 2",
"    </a>",
"    ). More than 50 percent of these women are asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/42\">",
"     42",
"    </a>",
"    ]. When symptoms do occur, vaginal discharge, intermenstrual vaginal bleeding, and post-coital bleeding may be noted. Poorly differentiated abdominal pain or lower abdominal pain may indicate upper genital tract involvement. While the physical examination is often unremarkable, mucopurulent cervical discharge, cervical friability, and cervical edema can be noted. Endocervical ulcers also may be seen.",
"   </p>",
"   <p>",
"    Although cervical ectopy has been traditionally associated with chlamydia, studies by our group have suggested that when cervical ectopy is strictly defined, it not found with increased frequency in patients with chlamydia infection compared to other adolescent women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/43\">",
"     43",
"    </a>",
"    ]. Chlamydial infection may be associated with an increased risk of cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dysuria-pyuria syndrome due to urethritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydial infection of the female urethra often accompanies cervicitis. Women with urethral infection complain of typical symptoms of a urinary tract infection (UTI) such as frequency and dysuria, and occasionally of lower abdominal pain. Urinalysis reveals pyuria, but no organisms are seen on Gram stain or in traditional culture. The differential diagnosis is low-colony count UTI (eg, infection caused by Staphylococcus saprophyticus), or urethritis due to other STD organisms, such as N. gonorrhoeae or Herpes simplex. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Perihepatitis (Fitzhugh-Curtis syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, patients with chlamydia infection develop perihepatitis, an inflammation of the liver capsule and adjacent peritoneal surfaces (",
"    <a class=\"graphic graphic_picture graphicRef50868 \" href=\"mobipreview.htm?23/17/23824\">",
"     picture 3",
"    </a>",
"    ). Perihepatitis is more commonly seen in PID, occurring in 5 to up to 15 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .) The pathogenesis of this entity is not fully understood but may involve either direct extension of infected material from the cul-de-sac through the peritoneum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphatics or an immunologically mediated mechanism.",
"   </p>",
"   <p>",
"    Perihepatitis should be suspected in persons with right-upper quadrant pain or pleuritic pain, in the clinical context of a lower genital tract infection. There are typically no associated liver enzyme abnormalities. Treatment is supportive, usually with nonsteroidal anti-inflammatory agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of women with chlamydia infection will develop upper genital tract involvement (pelvic inflammatory disease; PID) if left untreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/45\">",
"     45",
"    </a>",
"    ]. Women with PID may complain of lower abdominal pain, vaginal discharge, dysuria and constitutional symptoms, such as fever and chills. While PID caused by N. gonorrhoeae infection may be more acutely symptomatic, PID due to C. trachomatis tends to be associated with higher rates of subsequent infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of PID are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated chlamydia infection can increase the risk for premature rupture of the membranes and low birth weight. Maternal antibodies to the organism provide limited, if any, protection for the newborn. If the mother is untreated, 20 to 50 percent of newborns will develop conjunctivitis, and 10 to 20 percent will develop pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27992?source=see_link\">",
"     \"Chlamydia trachomatis infections in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional methods of screening for chlamydial infection require a speculum examination in women. These examinations are uncomfortable and also require a clinic visit and use of an examination room, sterile equipment, gowns, and trained clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninvasive screening options, such as urine testing or self-collected vaginal swabs are more acceptable to patients and require less resources. Urine based screening has the advantage also of increasing the number of women who are screened in outpatient clinics. Several nucleic acid amplification tests on urine are available for use with urine specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Nucleic acid amplification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Diagnostic methods include culture, nucleic acid amplification techniques, antigen detection, and genetic probes; microscopy is not used for the diagnosis of chlamydia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture methods are now limited to research and reference laboratories due to its expense. Culture should be used routinely only in cases of forensic investigation (eg, rape, child abuse).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nucleic acid amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification (NAAT) methodology consists of amplifying C. trachomatis DNA or RNA sequences using polymerase chain reaction (PCR), transcription-mediated amplification (TMA), or strand displacement amplification (SDA). These sensitive and specific tests have replaced poorly standardized cell culture methods as the \"gold standard\", and are the preferred diagnostic method, if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another advantage of NAATs is the ability to perform testing on urine as well as urethral and vaginal specimens. Since urine collection is noninvasive, it is a preferred method for patients and staff.",
"   </p>",
"   <p>",
"    A systematic review pooled data from 29 studies to assess the sensitivity and specificity of NAATs for C. trachomatis infection in urine specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/47\">",
"     47",
"    </a>",
"    ]. Summary estimates for sensitivity and specificity were calculated for urine and urethral sampling for three NAAT methods (using PCR, TMA, or SDA). The analysis demonstrated that the sensitivity and specificity of non-invasive testing was comparable to invasive testing, although more data was available for analysis on PCR testing than the other two methods as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the 14 studies of the PCR assay, the pooled sensitivity and specificity were 83 and 99.5 percent for urine samples and 86 and 99.6 percent for cervical samples.",
"     </li>",
"     <li>",
"      For the 4 studies of the TMA assay, the pooled sensitivity and specificity were 93 and 99 percent for urine samples and 97 and 99 percent for cervical samples.",
"     </li>",
"     <li>",
"      For the two studies of the SDA assay, the pooled sensitivity and specificity were 80 and 99 percent for urine samples and 94 and 98 percent for cervical samples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen detection requires invasive testing using a swab from the cervix or urethra. The sensitivity of this method is 80 to 95 percent compared to culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Genetic probe methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic probe methods require invasive testing using a direct swab from the cervix or urethra. The sensitivity of this assay is 80 to 95 percent compared to culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chlamydia rapid testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although NAAT testing has replaced culture as the new \"gold standard\", same-day results are not available. Furthermore, NAAT testing is too expensive for use in resource-limited settings. Several immunoassay-based tests are being developed, which are based on monoclonal antibody binding of chlamydial antigens from self-collected vaginal samples. These rapid tests provide results within 30 minutes of testing and are less expensive to perform and simple to interpret since testing results are reflected in a test strip color change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary data in a study of 1349 women attending STD clinics in the United Kingdom found that CRT provided rapid turnaround with high rates of patient acceptability and relatively good sensitivity (84 percent) and specificity (99 percent) compared to NAAT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/53\">",
"     53",
"    </a>",
"    ]. However, another study of rapid point-of-care testing among 278 asymptomatic sex workers in Guatemala demonstrated that the sensitivity of this assay was only 63 percent compared with PCR testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2068790\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervicitis may be caused by Chlamydia or Neisseria gonorrhea; less frequently cervicitis is associated with trichomonas, bacterial vaginosis, or herpes simplex virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42728/abstract/50\">",
"     50",
"    </a>",
"    ]. Persistent signs and symptoms of cervicitis may also be due to persistent abnormalities of vaginal flora following antibiotic exposure or to chemical irritants through douching. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CHLAMYDIA SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implementation of screening intervention trials has demonstrated a decline in chlamydial infection and the incidence of pelvic inflammatory disease (PID). The screening for chlamydia infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of Chlamydia trachomatis infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=see_link\">",
"     \"Treatment of Chlamydia trachomatis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/52/23362?source=see_link\">",
"       \"Patient information: Chlamydia and gonorrhea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"       \"Patient information: Chlamydia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/0/30721?source=see_link\">",
"       \"Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19608967\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chlamydia trachomatis is the most common bacterial cause of sexually transmitted infections among men and women. A significant proportion of patients are asymptomatic, thereby providing an ongoing reservoir for infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chlamydia trachomatis, a small gram-negative bacterium, is an obligate intracellular pathogen. Chlamydia cannot be cultured on routine artificial media. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 4,000,000 cases of C. trachomatis infection are estimated to occur annually in the United States (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for chlamydia infection include young age, multiple sex partners, inconsistent use of barrier contraceptives, and history of prior sexually transmitted infections. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period of symptomatic disease ranges from 7 to 14 days. (See",
"      <a class=\"local\" href=\"#H6322940\">",
"       'Incubation period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical infection is the most common site of infection, although more than 50 percent of women are asymptomatic. When symptoms do occur, vaginal discharge, intermenstrual vaginal bleeding, and post-coital bleeding may be reported. Poorly differentiated abdominal pain or lower abdominal pain may indicate early upper genital tract involvement. While the physical examination is often unremarkable, mucopurulent cervical discharge, cervical friability, and cervical edema may be seen. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cervicitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chlamydial infection of the female urethra often accompanies cervicitis. Women with urethral infection complain of typical symptoms of a urinary tract infection, such as frequency and dysuria. Urinalysis reveals pyuria, but no organisms are seen on Gram stain or on routine culture. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dysuria-pyuria syndrome due to urethritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 percent of women with chlamydia infection will develop pelvic inflammatory disease (PID) with upper genital tract involvement if left untreated. Women with PID may complain of lower abdominal pain, vaginal discharge, dysuria and constitutional symptoms, such as fever. PID can lead to chronic abdominal pain and infertility. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pelvic inflammatory disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of chlamydia is usually made with molecular methods, such as nucleic acid amplification (NAAT), which are highly sensitive and specific. Another advantage of NAATs is the ability to perform testing on urine as well as urethral and vaginal specimens. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervicitis may also be caused by Neisseria gonorrhea, trichomonas, bacterial vaginosis, or herpes simplex virus infection. (See",
"      <a class=\"local\" href=\"#H2068790\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/1\">",
"      Debattista J, Timms P, Allan J, Allan J. Immunopathogenesis of chlamydia trachomatis infections in women. Fertil Steril 2003; 79:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/2\">",
"      Lampe MF, Wong KG, Stamm WE. Sequence conservation in the major outer membrane protein gene among Chlamydia trachomatis strains isolated from the upper and lower urogenital tract. J Infect Dis 1995; 172:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/3\">",
"      Stothard DR, Boguslawski G, Jones RB. Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants. Infect Immun 1998; 66:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/4\">",
"      Pal S, Barnhart KM, Wei Q, et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999; 17:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/5\">",
"      Su H, Raymond L, Rockey DD, et al. A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells. Proc Natl Acad Sci U S A 1996; 93:11143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/6\">",
"      Rund S, Lindner B, Brade H, Holst O. Structural analysis of the lipopolysaccharide from Chlamydia trachomatis serotype L2. J Biol Chem 1999; 274:16819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/7\">",
"      Ingalls RR, Rice PA, Qureshi N, et al. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995; 63:3125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/8\">",
"      Wyrick PB, Knight ST, Paul TR, et al. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. J Infect Dis 1999; 179:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/9\">",
"      Ito JI, Lyons JM. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect Immun 1999; 67:5518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/10\">",
"      Igietseme JU, Ananaba GA, Bolier J, et al. The intercellular adhesion molecule type-1 is required for rapid activation of T helper type 1 lymphocytes that control early acute phase of genital chlamydial infection in mice. Immunology 1999; 98:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/11\">",
"      Persson K, Osser S, Birkelund S, et al. Antibodies to Chlamydia trachomatis heat shock proteins in women with tubal factor infertility are associated with prior infection by C. trachomatis but not by C. pneumoniae. Hum Reprod 1999; 14:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/12\">",
"      Peterson EM, Cheng X, Motin VL, de la Maza LM. Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect Immun 1997; 65:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/13\">",
"      LaVerda D, Albanese LN, Ruther PE, et al. Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease. Infect Immun 2000; 68:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/14\">",
"      Su H, Morrison R, Messer R, et al. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J Infect Dis 1999; 180:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/15\">",
"      Webster LA, Greenspan JR, Nakashima AK, Johnson RE. An evaluation of surveillance for Chlamydia trachomatis infections in the United States, 1987-1991. MMWR CDC Surveill Summ 1993; 42:21.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control, Division of Sexually Transmitted Diseases. 1997 Annual Report.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/17\">",
"      Quinn TC, Zenilman J, Rompalo A. Sexually transmitted diseases: advances in diagnosis and treatment. Adv Intern Med 1994; 39:149.",
"     </a>",
"    </li>",
"    <li>",
"     Alexander, LA, Cates, JR, Herndon, N, Ratcliff, JM. Sexually Transmitted Diseases in America. Kaiser Family Foundation, Menlo Park, CA. December 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/19\">",
"      Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Chlamydia trachomatis genital infections--United States, 1995. MMWR Morb Mortal Wkly Rep 1997; 46:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/21\">",
"      Gaydos CA, Howell MR, Pare B, et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998; 339:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/22\">",
"      Cook RL, St George K, Lassak M, et al. Screening for Chlamydia trachomatis infection in college women with a polymerase chain reaction assay. Clin Infect Dis 1999; 28:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/23\">",
"      Burstein GR, Waterfield G, Joffe A, et al. Screening for gonorrhea and chlamydia by DNA amplification in adolescents attending middle school health centers. Opportunity for early intervention. Sex Transm Dis 1998; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/24\">",
"      Neu NM, Grumet S, Saiman L, et al. Genital chlamydial disease in an urban, primarily Hispanic, family planning clinic. Sex Transm Dis 1998; 25:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/25\">",
"      Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/26\">",
"      Sturm-Ramirez K, Brumblay H, Diop K, et al. Molecular epidemiology of genital Chlamydia trachomatis infection in high-risk women in Senegal, West Africa. J Clin Microbiol 2000; 38:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/27\">",
"      Kilmarx PH, Black CM, Limpakarnjanarat K, et al. Rapid assessment of sexually transmitted diseases in a sentinel population in Thailand: prevalence of chlamydial infection, gonorrhoea, and syphilis among pregnant women--1996. Sex Transm Infect 1998; 74:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/28\">",
"      Warszawski J, Meyer L, Weber P. Criteria for selective screening of cervical Chlamydia trachomatis infection in women attending private gynecology practices. Eur J Obstet Gynecol Reprod Biol 1999; 86:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/29\">",
"      Parish WL, Laumann EO, Cohen MS, et al. Population-based study of chlamydial infection in China: a hidden epidemic. JAMA 2003; 289:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/30\">",
"      Stamm WE, Koutsky LA, Benedetti JK, et al. Chlamydia trachomatis urethral infections in men. Prevalence, risk factors, and clinical manifestations. Ann Intern Med 1984; 100:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/31\">",
"      Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/32\">",
"      Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/33\">",
"      Phillips RS, Hanff PA, Holmes MD, et al. Chlamydia trachomatis cervical infection in women seeking routine gynecologic care: criteria for selective testing. Am J Med 1989; 86:515.",
"     </a>",
"    </li>",
"    <li>",
"     Stamm WE, Mardh PA. Chlamydia trachomatis. In: Sexually transmitted diseases, Second Edition, Holmes KK, Mardh PA, Sparling PF, Wiesner PJ (Eds), McGraw-Hill, New York 1990. p.917.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/35\">",
"      Stergachis A, Scholes D, Heidrich FE, et al. Selective screening for Chlamydia trachomatis infection in a primary care population of women. Am J Epidemiol 1993; 138:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/36\">",
"      Lin JS, Donegan SP, Heeren TC, et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998; 178:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/37\">",
"      Vogels WH, van Voorst Vader PC, Schr&ouml;der FP. Chlamydia trachomatis infection in a high-risk population: comparison of polymerase chain reaction and cell culture for diagnosis and follow-up. J Clin Microbiol 1993; 31:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/38\">",
"      Burstein GR, Gaydos CA, Diener-West M, et al. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA 1998; 280:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/39\">",
"      Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/40\">",
"      Kilmarx PH, Limpakarnjanarat K, Mastro TD, et al. HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. AIDS 1998; 12:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/41\">",
"      Geisler WM, Wang C, Morrison SG, et al. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008; 35:119.",
"     </a>",
"    </li>",
"    <li>",
"     Stamm WE, Holmes KK. Chlamydia trachomatis infections of the adult. In: Sexually Transmitted Diseases, Second Edition, Holmes KK, Mardh PA, Sparling PF, et al (Eds), McGraw-Hill, New York 1990. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/43\">",
"      Jacobson DL, Peralta L, Graham NM, Zenilman J. Histologic development of cervical ectopy: relationship to reproductive hormones. Sex Transm Dis 2000; 27:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/44\">",
"      Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/45\">",
"      Cates W Jr, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991; 164:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/46\">",
"      Tubal infertility: serologic relationship to past chlamydial and gonococcal infection. World Health Organization Task Force on the Prevention and Management of Infertility. Sex Transm Dis 1995; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/47\">",
"      Cook RL, Hutchison SL, &Oslash;stergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005; 142:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/48\">",
"      Quinn TC, Welsh L, Lentz A, et al. Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from women and men attending sexually transmitted disease clinics. J Clin Microbiol 1996; 34:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/49\">",
"      Jespersen DJ, Flatten KS, Jones MF, Smith TF. Prospective comparison of cell cultures and nucleic acid amplification tests for laboratory diagnosis of Chlamydia trachomatis Infections. J Clin Microbiol 2005; 43:5324.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/51\">",
"      LaMontagne DS, Fenton KA, Randall S, et al. Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening. Sex Transm Infect 2004; 80:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/52\">",
"      Greer L, Wendel GD Jr. Rapid diagnostic methods in sexually transmitted infections. Infect Dis Clin North Am 2008; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/53\">",
"      Mahilum-Tapay L, Laitila V, Wawrzyniak JJ, et al. New point of care Chlamydia Rapid Test--bridging the gap between diagnosis and treatment: performance evaluation study. BMJ 2007; 335:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42728/abstract/54\">",
"      Sabid&oacute; M, Hern&aacute;ndez G, Gonz&aacute;lez V, et al. Clinic-based evaluation of a rapid point-of-care test for detection of Chlamydia trachomatis in specimens from sex workers in Escuintla, Guatemala. J Clin Microbiol 2009; 47:475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7591 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42728=[""].join("\n");
var outline_f41_46_42728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19608967\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors for infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased transmission of HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6322940\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cervicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dysuria-pyuria syndrome due to urethritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Perihepatitis (Fitzhugh-Curtis syndrome)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nucleic acid amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Genetic probe methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chlamydia rapid testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2068790\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CHLAMYDIA SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19608967\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7591|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/40/26253\" title=\"figure 1\">",
"      Chlamydial infection by gender",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7591|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/55/39798\" title=\"picture 1\">",
"      Chlamydia reticulate bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/17/36114\" title=\"picture 2\">",
"      Chlamydia cervicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/17/23824\" title=\"picture 3\">",
"      Perihepatitis in Chlamydia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/0/30721?source=related_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_46_42729="Intraoperative fluid management";
var content_f41_46_42729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraoperative fluid management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42729/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42729/contributors\">",
"     Girish P Joshi, MB, BS, MD, FFARCSI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42729/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/46/42729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/46/42729/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/46/42729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1058520434\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of intravascular fluid volume is important to achieve optimal perioperative outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Fluid therapy remains a controversial topic in perioperative anesthetic management with variable recommendations for the composition and volume of fluid given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The main reason for such variability is that evidence regarding best fluid management with respect to clinically important outcomes is limited and of low quality.",
"   </p>",
"   <p>",
"    Factors that alter intravascular volume perioperatively, measurement of fluid status in the operating room, and strategies to choose the composition and volume of fluid in the context of surgical losses associated with elective surgical procedures (not trauma or emergent surgery) will be reviewed here. &nbsp;",
"   </p>",
"   <p>",
"    General issues pertaining to maintenance and replacement fluid and non-operative fluid management are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254312679\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE CHANGES IN VOLUME AND TISSUE PERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing surgery are at risk for either a reduction or an increase in fluid volume and for a reduction in tissue perfusion. The definitions of these terms will be briefly reviewed in this section, while the clinical determination of volume status is discussed in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694830816\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three terms that need be understood when discussing intraoperative fluid management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypovolemia",
"      </strong>",
"      &ndash; Hypovolemia refers to a reduction in the intravascular fluid volume below normal due to fluid losses from a variety of sites. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypervolemia",
"      </strong>",
"      &ndash; Hypervolemia refers to an increase in intravascular fluid volume.",
"     </li>",
"     <li>",
"      <strong>",
"       Tissue perfusion",
"      </strong>",
"      &ndash; Tissue perfusion refers to the ability to deliver oxygen at the tissue level. Reductions in tissue perfusion may be seen in association with hypovolemia, normovolemia, or hypervolemia. Reduced blood flow in the tissues can be due to reduced stroke volume or due to peripheral vasoconstriction even when stroke volume is adequate. Tissue perfusion can be also be inadequate because of an increased oxygen demand that is not met. With associated cardiac problems, a reduction in tissue perfusion is often associated with hypervolemia due to retention of administered fluid.",
"      <br/>",
"      <br/>",
"      The main indicator of reduced tissue perfusion is lactic acidosis. Reduced tissue perfusion is not necessarily associated with a significant reduction in blood pressure. The vasoconstrictive response to reduced tissue perfusion is activation of the sympathetic nervous system and the renin-angiotensin system. These vasoconstrictors raise the blood pressure, which can return to the baseline value, but reduce perfusion to the kidneys, gastrointestinal tract, and skin in an attempt to preserve perfusion to the vital organs, the heart and the brain. However, during surgery, this appropriate vasoconstrictive response may be impaired by anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254314149\">",
"    <span class=\"h2\">",
"     Hypovolemia and reduced tissue perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemia is associated with low cardiac output states that reduce tissue perfusion and, if severe, can lead to shock and multiorgan failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The major causes of hypovolemia during surgery are preoperative fasting, anesthesia-related vasodilation, and surgical bleeding.",
"   </p>",
"   <p>",
"    The predictors of acute kidney injury after noncardiac surgery were evaluated in a series of 15,102 patients with normal renal function at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/7\">",
"     7",
"    </a>",
"    ]. Acute kidney injury developed in 121 patients (0.8 percent), with 14 patients (0.1 percent) requiring renal replacement therapy. Independent intraoperative variables predictive of acute kidney injury included the use of a vasopressor infusion, total vasopressor dose administered, and diuretic administration. However, other factors other than intraoperative hypovolemia can also contribute to the development of acute kidney injury, and acute kidney injury can occur in patients who are normotensive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Splanchnic vasoconstriction, which diverts blood away from the splanchnic bed in favor of vital organs such as the heart and brain, is an early response to a reduction in tissue perfusion. The reduction in splanchnic perfusion is usually disproportionately greater than that seen in other vascular beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, gut mucosal hypoperfusion is an early consequence of perioperative hypovolemia and inadequate cardiac output, and is demonstrable before reductions in systemic blood pressure and urine output. Monitoring mucosal perfusion may be one way to identify inadequate tissue perfusion. (See",
"    <a class=\"local\" href=\"#H15026187\">",
"     'Monitoring the microcirculation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254314156\">",
"    <span class=\"h2\">",
"     Hypervolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypervolemia due to retention of fluid given during surgery is common. Marked postoperative fluid overload, defined as weight gain of more than 10 percent above the preoperative weight, has been associated with increases in morbidity, length of intensive care unit stay, and postoperative mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/9\">",
"     9",
"    </a>",
"    ]. The apparent adverse effect of marked hypervolemia on prognosis may be related to two factors: first, it is a marker for sicker patients, as is seen with excessive fluid requirements due to hemodynamic instability or massive transfusion due to bleeding, and second, overhydration itself may have deleterious effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/10\">",
"     10",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development of pulmonary edema, particularly in patients with a history of heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link\">",
"       \"Perioperative heart failure in noncardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased extravascular fluid in the lung tissue impairs oxygen exchange and increases the risk for postoperative respiratory failure and pneumonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=see_link&amp;anchor=H32#H32\">",
"       \"Overview of the management of postoperative pulmonary complications\", section on 'Pulmonary edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased extracellular fluid in the bowel can lead sequentially to gastrointestinal edema, decreased gastrointestinal motility, and ileus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/12\">",
"       12",
"      </a>",
"      ]. In addition, for patients undergoing bowel surgery, intestinal edema can increase tension at bowel anastomoses and may contribute to anastomotic dehiscence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Massive fluid resuscitation may be associated with acute ascites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/13\">",
"       13",
"      </a>",
"      ] which, along with bowel edema, can contribute to the development of abdominal compartment syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=see_link\">",
"       \"Abdominal compartment syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Marked tissue edema can impair wound healing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5177?source=see_link\">",
"       \"Wound healing and risk factors for non-healing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excess intravascular fluid can lead to coagulation abnormalities by dilution. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H3#H3\">",
"       \"Massive blood transfusion\", section on 'Alterations in the coagulation system'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254314205\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING VOLUME STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors affect volume status, including preoperative factors, anesthesia, and the nature of the surgical procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preoperative fasting overnight for approximately 10 hours should not significantly reduce the intravascular volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/15\">",
"       15",
"      </a>",
"      ]. Preoperative dehydration is avoided by limiting the period of fasting and encouraging patients to consume clear oral liquids (eg, water) up to two hours preoperatively.",
"     </li>",
"     <li>",
"      Mechanical bowel preparation is associated with osmotic fluid loss from the gastrointestinal tract which can be avoided by not using mechanical bowel preparation, whenever possible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16762?source=see_link&amp;anchor=H125365066#H125365066\">",
"       \"Surgical oncologic principles for the resection of colon cancer\", section on 'Bowel preparation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders such as bowel obstruction or pancreatitis can cause interstitial edema and volume loss from inflammation, the magnitude of which depends upon the duration of the disease process and resuscitative efforts. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link&amp;anchor=H2#H2\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypovolemia in patients with severe bleeding may require surgical control of bleeding before volume repletion can be achieved. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link\">",
"       \"Initial evaluation and management of shock in adult trauma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anesthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sympathetic blockade during neuraxial anesthesia can lead to hypotension that is induced by increased venous capacitance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dilation of arteriolar resistance vessels.",
"     </li>",
"     <li>",
"      Some anesthetic and analgesic drugs cause vasodilation and consequent relative hypovolemia and hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Fluid retention also occurs through the effects of inhaled anesthetics on the kidneys. Intraoperative fluid load can be limited by avoiding deep general anesthesia. However, anesthesia should not be so light that the patient is at risk for intraoperative awareness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=see_link\">",
"       \"Awareness with recall following general anesthesia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory fluid losses are associated with mechanical ventilation. To minimize these losses, a humidified circuit is used and hyperventilation is avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sudden hemorrhage during surgery acutely decreases the intravascular volume.",
"     </li>",
"     <li>",
"      Coagulopathy due to dilution or hypothermia aggravates blood loss.",
"     </li>",
"     <li>",
"      Prolonged operative time, particularly with open surgical exposures, may lead to increased bowel edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evaporative water loss from abdominal exposure is of clinical importance in time-consuming procedures with exposure and exteriorization of the intestines. Lesser exposures of the abdominal or chest cavity are associated with small evaporative losses that are usually less than 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/19\">",
"       19",
"      </a>",
"      ]. Evaporative losses from exposed wounds are negligible.",
"     </li>",
"     <li>",
"      Inadvertent compression on the inferior vena cava or other major veins (eg, with packs or retractors) can dramatically reduce venous return, leading to an apparent hypovolemic state. Venous return can also be transiently reduced by abdominal insufflation during laparoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254311231\">",
"    <span class=\"h1\">",
"     MONITORING VOLUME STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goal of intraoperative fluid therapy is to maintain tissue perfusion by optimizing intravascular volume status and stroke volume. The determination of intravascular volume in the operating room remains a challenge because of a rapidly changing physiology that is primarily due to cardiovascular responses to anesthetic agents and intraoperative volume losses. In addition, the underlying condition that led to the need for surgical intervention may be associated with a suboptimal preoperative volume status. (See",
"    <a class=\"local\" href=\"#H254314205\">",
"     'Factors affecting volume status'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H787888996\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The determination and monitoring of volume status in the operating room depends primarily upon hemodynamic monitoring, since other clinical methods routinely used to assess volume status are unavailable in the anesthetized patient. In addition, acute changes in volume status are not immediately reflected in typical laboratory parameters. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link&amp;anchor=H19#H19\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Laboratory abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the clinical practice of anesthesia, routine monitoring of physiological parameters such as heart rate, arterial blood pressure, central venous pressure, peripheral oxygen saturation, and urine output are frequently used to assess intravascular volume status and guide fluid therapy. However, these parameters may not detect subclinical hypovolemic states that are common in the perioperative period. A patient can have a normal heart rate, blood pressure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine output but may be hypovolemic or hypervolemic. The central venous pressure and pulmonary artery occlusion pressure are inaccurate surrogates to determine cardiac preload and do not detect or predict impending pulmonary edema indicative of hypervolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/11,20,21\">",
"     11,20,21",
"    </a>",
"    ]. Thus, the use of these parameters to guide fluid therapy may result in hypovolemia or hypervolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although oliguria (urine output less than 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) is commonly used as an indicator of hypovolemia, evidence supporting this practice is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/7\">",
"     7",
"    </a>",
"    ] and intraoperative oliguria is not a predictor of acute kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/22\">",
"     22",
"    </a>",
"    ]. Inhaled anesthetics and surgical stress can reduce the urine output even in the presence of euvolemia and adequate tissue perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Thus, fluid administration solely for the purpose of increasing urine output is not indicated and may lead to fluid overload.",
"   </p>",
"   <p>",
"    Measures of global oxygenation such as mixed venous oxygen saturation (SvO2) or central venous oxygen saturation (ScvO2) obtained continuously using fiberoptic catheters or intermittently from blood gas analysis have been used to guide fluid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/23\">",
"     23",
"    </a>",
"    ]. However, these indicators do not always reflect changes in oxygen delivery since oxygen consumption varies during the perioperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254311286\">",
"    <span class=\"h2\">",
"     Dynamic parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limitations of the routinely used \"static\" parameters discussed in the preceding section, dynamic indices have been used to guide fluid therapy and may be superior in detecting the hemodynamic response to a fluid challenge (ie, volume responsiveness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/21,23,25-27\">",
"     21,23,25-27",
"    </a>",
"    ]. Dynamic variables include use of systolic pressure variation, pulse pressure variation, or stroke volume variation derived from the arterial wave form, plethysmographic wave form (from pulse oximetry), or monitors that use arterial wave analysis or an esophageal Doppler device to calculate stroke volume. Although dynamic parameters appear to be better than static parameters, there is no evidence to suggest that any one method that uses dynamic parameters is better than another in guiding intraoperative fluid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15026173\">",
"    <span class=\"h3\">",
"     Stroke volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid therapy guided by stroke volume measured using a transesophageal Doppler or using arterial wave form analysis has been shown to improve perioperative outcome. Flow in the descending aorta, measured with transesophageal Doppler, provides a reliable assessment of stroke volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/6,23,28-33\">",
"     6,23,28-33",
"    </a>",
"    ]. A meta-analysis identified five trials that included 420 patients undergoing major abdominal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients whose fluid therapy requirements were based upon Doppler parameters had a significantly shorter hospital stay, lower incidence of complications, and fewer intensive care unit admissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Mortality rates were not significantly affected.",
"    <br/>",
"    <br/>",
"    Esophageal Doppler can also be used to evaluate the patient&rsquo;s volume responsiveness by plotting the relationship between right atrial pressure and cardiac output or stroke volume following a fluid challenge (ie, generating a Frank-Starling curve). Increases in cardiac output or stroke volume with colloid or crystalloid solutions are indicative of volume responsiveness. In such patients, intravenous fluids can be given until there is no further response. (See",
"    <a class=\"local\" href=\"#H626508222\">",
"     'Goal-directed fluid therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15026180\">",
"    <span class=\"h3\">",
"     Respiratory variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indices based upon respiratory variation are also used to guide intraoperative fluid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/23,25,26,36,37\">",
"     23,25,26,36,37",
"    </a>",
"    ]. In the mechanically ventilated patient who is not triggering the ventilator, inspiration increases intrathoracic pressure and sequentially reduces right ventricular filling volume, right ventricular stroke volume, and left ventricular stroke volume. The opposite occurs during expiration. Thus, changes in venous return (ie, intravascular volume) lead to variations in the stroke volume (ie, stroke volume variation), systolic blood pressure (ie, systolic pressure variation), pulse pressure (ie, pulse pressure variation), and plethysmographic waveform, assuming that the arterial vasomotor tone and cardiac function remain constant. The normal respiratory variation of the systolic pressure (",
"    <a class=\"graphic graphic_figure graphicRef85848 \" href=\"mobipreview.htm?0/12/194\">",
"     figure 1",
"    </a>",
"    ), pulse pressure, or stroke volume is less than 10 percent (",
"    <a class=\"graphic graphic_figure graphicRef86275 \" href=\"mobipreview.htm?21/34/22051\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/38\">",
"     38",
"    </a>",
"    ]. Greater variations suggest fluid responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, fluid boluses are administered if respiratory variation is greater than 10 to 15 percent.",
"   </p>",
"   <p>",
"    Each of the types of dynamic indices (systolic pressure variation, pulse pressure variation, and stroke volume variation) has its advantages and disadvantages (",
"    <a class=\"graphic graphic_table graphicRef85850 \" href=\"mobipreview.htm?20/32/21003\">",
"     table 1",
"    </a>",
"    ). Although indices of respiratory variation can be computed (manually or automatically), visual estimation may be adequate to guide fluid therapy. In one study, the need for a fluid bolus based upon systolic pressure variations that were visually estimated from the arterial waveform were compared with computed values and only 1 percent of treatments based upon visual estimation were erroneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    There are a number of limitations to using respiratory variation to guide fluid therapy. Respiratory variation cannot be used in spontaneously breathing patients, patients with cardiac arrhythmia, with tidal volumes less than 8",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    high positive end-expiratory pressures, use of vasoactive drugs, during open chest procedures, in the presence of elevated intraabdominal pressure, or in patients with right ventricular failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15026187\">",
"    <span class=\"h3\">",
"     Monitoring the microcirculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic monitoring has been expanded from the macrocirculation to microcirculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/24\">",
"     24",
"    </a>",
"    ]. Some of the monitoring devices that are being investigated include intravital microscopy, laser Doppler flowmetry, sublingual capnometry, near-infrared spectroscopy, and reflection spectrophotometry. The noninvasive measures of tissue oxygenation such as infrared oximetry and differences in sublingual PCO",
"    <sub>",
"     2",
"    </sub>",
"    and arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    are reported to detect subclinical hypoperfusion. However, the use of these monitoring devices is limited as they are prone to artifact. Further clinical evaluation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058523188\">",
"    <span class=\"h1\">",
"     FLUID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluids used to optimize volume status are broadly classified as crystalloids and colloids (",
"    <a class=\"graphic graphic_table graphicRef63639 \" href=\"mobipreview.htm?18/17/18717\">",
"     table 2",
"    </a>",
"    ). Crystalloids are solutions of electrolytes and sterile water (eg, saline, Ringer&rsquo;s lactate) that may be isotonic, hypotonic, or hypertonic with respect to plasma. Colloids are human plasma derivatives (eg, human albumin, fresh frozen plasma) or semisynthetic (eg, dextrans, gelatins, and hydroxyethyl starch) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/43\">",
"     43",
"    </a>",
"    ]. Colloids may be dissolved in isotonic saline or in a balanced electrolyte solution (electrolyte concentration similar to plasma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crystalloid and colloid solutions have different volume effects. While about 20 percent of crystalloid volume remains in the intravascular compartment, 80 percent enters the much larger interstitial compartment over 25 to 30 minutes. Thus the duration of maximal plasma volume expansion is relatively short [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, colloids are retained in the intravascular compartment, resulting in significant plasma expansion for 2 to 36 hours (",
"    <a class=\"graphic graphic_table graphicRef63639 \" href=\"mobipreview.htm?18/17/18717\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4057778\">",
"    <span class=\"h2\">",
"     Crystalloid solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saline (sodium chloride) is mixed in varying dilutions from 0.25 to 3 percent (",
"    <a class=\"graphic graphic_table graphicRef63639 \" href=\"mobipreview.htm?18/17/18717\">",
"     table 2",
"    </a>",
"    ). Balanced electrolyte solution (eg, Ringer's lactate) has an electrolyte composition similar to plasma. When administered in large volumes, normal (0.9 percent) saline can, by dilution, cause a normal anion gap metabolic acidosis, (ie, hyperchloremic metabolic acidosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/3,47-51\">",
"     3,47-51",
"    </a>",
"    ], that may be severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. For this reason, balanced electrolyte solutions are preferred and conventional saline solutions are generally not used in the operating room. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=see_link&amp;anchor=H197401411#H197401411\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Dilution acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4057785\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35630849\">",
"    <span class=\"h3\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydroxyethyl starches (HES) are identified by three numbers corresponding to concentration, molecular weight, and molar substitution. As an example, Hespan&reg; is HES 6 percent",
"    <span class=\"nowrap\">",
"     (600/0.75).",
"    </span>",
"    The concentration influences the initial volume effect (eg, 6 percent HES is iso-oncotic, replacing an equal volume of blood loss; 10 percent HES is hyperoncotic with volume effect of about 145 percent). The molecular weight is an average of the wide range in size of molecules, which break down and are renally excreted. Molar substitution (number of hydroxyethyl groups per glucose molecule) is the most clinically significant number as it relates to the rate of enzymatic degradation of the starch polymer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35630868\">",
"    <span class=\"h3\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many versions of HES; the newer generations are less toxic than older generations because they have a lower molar substitution (eg, the older",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/13/9430?source=see_link\">",
"     hetastarch",
"    </a>",
"    has seven substituted hydroxyethyls per 10 glucoses, noted as 0.7; the newest,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/60/30661?source=see_link\">",
"     tetrastarch",
"    </a>",
"    , has four substitutions, noted as 0.4). Compared to less substituted HES, highly substituted HES degrades more slowly and thus accumulates in plasma, which increases toxicity without improving volume efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal toxicity of HES depends on the level of molar substitution in the specific product, and thus is low in surgical patients who receive low substituted HES. In a meta-analysis of randomized trials in surgical patients, there was no difference in the incidence of renal impairment between patients who received low substituted HES (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/60/30661?source=see_link\">",
"     tetrastarch",
"    </a>",
"    ) and those who received other forms of fluid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the intensive care unit, renal toxicity is seen even with low substituted HES, possibly because of concurrent sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/56\">",
"     56",
"    </a>",
"    ]. In a randomized trial of 7000 patients admitted to an intensive care unit, the incidence of renal replacement therapy was greater (7.0 versus 5.8 percent) in those resuscitated with HES 6 percent",
"    <span class=\"nowrap\">",
"     (130/0.4)",
"    </span>",
"    than in those receiving saline (RR 1.21, 95% CI 1.00-1.45) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a 2010 Cochrane review found an overall increased risk of author-defined kidney failure in those receiving HES, this review included patients who received highly substituted HES and there was insufficient evidence to assess differences between HES products with respect to clinical renal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HES products decrease circulating plasma concentrations of coagulation factor VIII and von Willebrand factor, and impair platelet reactivity, but the low substituted HES solutions (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/27/14772?source=see_link\">",
"     pentastarch",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/60/30661?source=see_link\">",
"     tetrastarch",
"    </a>",
"    ) have minimal clinical influence on hemostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/59\">",
"     59",
"    </a>",
"    ]. In a pooled analysis of seven randomized trials comparing the use during surgery of low substituted HES 6 percent",
"    <span class=\"nowrap\">",
"     (130/0.4)",
"    </span>",
"    versus more highly substituted HES 6 percent",
"    <span class=\"nowrap\">",
"     (200/0.5),",
"    </span>",
"    use of the lower molar substitution product was associated with lower blood loss (by 404 mL, p = 0.006) and transfusion volumes (by 137 mL, p = 0.004) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4057814\">",
"    <span class=\"h2\">",
"     Plasma and plasma derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma components (eg, fresh frozen plasma, cryoprecipitate) are biological products prepared by centrifugation of whole blood or plasma. Plasma derivatives are prepared by a plasma fractionation process (eg, albumin, coagulation protein concentrates). Whether to use plasma-derived versus synthetic albumin remains controversial. Human albumin is expensive and its benefits over synthetic colloids (eg, hydroxyethyl starch) have not been clearly demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=see_link\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4057821\">",
"    <span class=\"h2\">",
"     Blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood is preferentially used to replace intraoperative blood loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24073?source=see_link\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4057828\">",
"    <span class=\"h2\">",
"     Gelatins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gelatins have a volume effect of 70 to 80 percent, are inexpensive, and have minimal effects on coagulation or renal function (",
"    <a class=\"graphic graphic_table graphicRef63639 \" href=\"mobipreview.htm?18/17/18717\">",
"     table 2",
"    </a>",
"    ). However, they are rapidly excreted in the urine and thus have a short duration of action (two to three hours), are not readily available in the United States, and have the potential to cause anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/43\">",
"     43",
"    </a>",
"    ]. A systematic review identified 40 trials published over a 25-year period involving 3275 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/61\">",
"     61",
"    </a>",
"    ]. From the 15 studies that reported mortality, no significant differences were seen between the gelatin and control groups (relative risk 1.12, 95% CI 0.87-1.44). In three trials that reported the incidence of acute kidney injury, no significant increase was found related to gelatin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=see_link&amp;anchor=H11#H11\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Colloids and plasma expanders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4057835\">",
"    <span class=\"h2\">",
"     Dextrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not used for fluid replacement, dextrans are used for thromboembolic prophylaxis in vascular procedures due to their effects on coagulation. Dextrans have a volume effect of 100 to 200 percent depending upon their molecular weight and concentration. Some dextrans are hyperoncotic and mobilize fluid from the extravascular space into intravascular space because of their high osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/62\">",
"     62",
"    </a>",
"    ]. On the other hand, others are iso-oncotic and thus exert a 100 percent volume effect. Dextrans are inexpensive and can be stored for approximately 10 years at room temperature. Complications include bleeding when used in higher than recommended doses, anaphylactoid reactions, acute kidney injury, and issues with cross-matching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254311346\">",
"    <span class=\"h1\">",
"     FLUID STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative fluid requirements depend upon multiple factors including the patient's preoperative volume status, preoperative comorbidities, age, anesthetic technique, and nature of the surgery. Fluid therapy is aimed at restoring and maintaining euvolemia. Fluid therapy in the operating room has traditionally been guided by fixed-volume algorithms in which substantial amounts of fluids are administered, but a growing body of evidence suggests that, for major surgical procedures, restricting intraoperative fluid administration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    using a goal-directed approach decreases perioperative morbidity and possibly mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/1-3,6,28-31,34\">",
"     1-3,6,28-31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A balanced approach to fluid management selects an appropriate fluid (crystalloid or colloid) depending upon the desired effect. As an example, maintenance of hemodynamic stability is achieved by replacement of plasma losses with colloid on a volume-to-volume basis and crystalloids are used for maintenance fluid therapy with replacement of sensible and insensible losses using a balanced electrolyte solution (0.5 to 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) or using a goal-directed approach. By avoiding replacement of nonanatomic third space losses and not preloading, undesirable excesses of crystalloid volume are prevented without encountering intraoperative hemodynamic instability or reduced urinary output (&lt;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour).",
"   </p>",
"   <p>",
"    It is critical to understand that &lsquo;static&rsquo; variables such as heart rate, arterial blood pressure, and cardiac filling pressures to guide fluid therapy have limitations. Thus, the use of &ldquo;dynamic&rdquo; variables such as stroke volume or systolic or pulse pressure variation are preferred. It is important to monitor multiple variables and assess changes over time (ie, use trends). (See",
"    <a class=\"local\" href=\"#H254311231\">",
"     'Monitoring volume status'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This section below reviews several different fluid strategies, followed by a discussion of how to choose a fluid strategy that is appropriate for the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626508208\">",
"    <span class=\"h2\">",
"     Fixed volume therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is increasingly accepted that fixed-volume fluid administration algorithms should be",
"    <strong>",
"     abandoned",
"    </strong>",
"    due to a tendency to cause fluid overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/6,10,63,64\">",
"     6,10,63,64",
"    </a>",
"    ]. Fixed volume algorithms use pre-determined fluid administration algorithms including fluid preloading for neuraxial blockade, and fluid replacement of third space losses, insensible losses, and urinary losses. With fixed volume regimens, the initial blood loss (usually 500 to 1000 mL) is replaced with three times the amount in crystalloid (ie, 1500 to 3000 mL crystalloid); however, the rationale for this regimen was never clear.",
"   </p>",
"   <p>",
"    Instead of fluid preloading, a better approach uses vasopressor agents to treat hypotension due to anesthetic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuraxial blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, it may be difficult to determine whether fluid loss or anesthesia is responsible for the hypotension. (See",
"    <a class=\"local\" href=\"#H254311231\">",
"     'Monitoring volume status'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626508215\">",
"    <span class=\"h2\">",
"     Restrictive fluid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For major elective surgical procedures, fluid regimens that minimize fluid administration may be more appropriate than fixed-volume therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/1,2,6,67,68\">",
"     1,2,6,67,68",
"    </a>",
"    ]. Restrictive fluid therapy avoids fluid overload by replacing only the fluid that is lost during surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/6\">",
"     6",
"    </a>",
"    ]. Vasopressor agents may be more frequently administered during restrictive fluid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/69\">",
"     69",
"    </a>",
"    ]. A potential disadvantage is that a restrictive fluid regimen may lead to hypovolemia that may not be clinically appreciated.",
"   </p>",
"   <p>",
"    A systematic review and metaanalysis found that restricted fluid therapy in patients undergoing major abdominal procedures significantly reduces the risk for pneumonia (risk ratio [RR] 2.16, 95% CI 1.04-4.47) and pulmonary edema (RR 2.85, 95% CI 1.13-13.07), improves bowel recovery (mean difference to time of first bowel movement -0.76 days, 95% CI -1.58 to -0.03, mean time to passage of flatus -0.54 days, 95% CI, -0.99 to -0.08) and shortens length of stay (mean difference -1.99 days, 95% CI -3.43 to -0.49) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/70\">",
"     70",
"    </a>",
"    ]. However, the studies included are limited by small sample size, number of events, and a lack of consistency in study design with variations in the types of fluids used (ie, crystalloids versus colloids) and in perioperative management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626508222\">",
"    <span class=\"h2\">",
"     Goal-directed fluid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goal-directed fluid therapy includes administration of fluids to achieve a certain goal (eg, optimizing stroke volume) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/6,28-30\">",
"     6,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Goal-directed therapy is generally used in patients undergoing major surgical procedures or in those with significant cardiac disease. At the start of anesthesia, an arterial line is placed and connected to a monitor that provides stroke volume; baseline stroke volume is obtained. A bolus of 200 to 250 mL of fluid is given and the change in stroke volume from the baseline is calculated. If the change is more than 10 to 15 percent another bolus is given, but if the change in stroke volume is less than 10 to 15 percent that stroke volume becomes a new baseline value. The stroke volume is continuously monitored for changes; if it falls by 10 to 15 percent, a bolus is given. Continued monitoring determines the need for additional fluid boluses. It is critical that trends in stroke volume are used rather than absolute values.",
"   </p>",
"   <p>",
"    Animal studies show improved microcirculatory flow using a goal-directed approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/45,46,71-73\">",
"     45,46,71-73",
"    </a>",
"    ]. Studies that have reported improved clinical outcomes have used colloid solutions (eg, hydroxyethyl starch).",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis identified 23 trials evaluating goal-directed fluid therapy compared with non-goal-direct therapy. Goal-directed fluid therapy has a lower risk of pneumonia (risk ratio [RR] 0.7, 95% CI 0.6-0.9), renal complications (RR 0.7, 95% CI 0.5-0.9), and a shorter length of hospital stay (mean reduction 2 days, 95% CI 1-3) compared with not using GD therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/70\">",
"     70",
"    </a>",
"    ]. In another metaanalysis, a similar reduction was seen in length of stay (weighted reduction 2.3 days, 95% CI 1.8-2.9) for goal-directed therapy compared with control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, four studies that evaluated return of bowel function demonstrated significantly reduced time to resumption of an oral diet (weighted difference 1.7 days, 95% CI 1.5-1.9) in those managed with goal-directed fluid therapy. Other studies have also found a reduced incidence of postoperative nausea, vomiting, and ileus with goal-directed therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of intravascular fluid optimization with goal-directed fluid therapy may be an important factor. In a trial that randomly assigned 108 patients undergoing elective colorectal resection to standard fluid therapy versus goal-directed therapy, goal-directed therapy was associated with significant reductions in postoperative hospital stay (7 versus 9 days), intermediate or major postoperative complications (2 versus 15 percent) and the time to resumption of an oral diet (2 versus 4 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/75\">",
"     75",
"    </a>",
"    ]. Although the total volume of fluid (crystalloid plus colloid) administered between the groups was similar, the goal-directed approach was associated with a larger volume of colloid administered in the early intraoperative period, suggesting that early optimization is important. Although early intravascular volume optimization may be important, administration of prophylactic fluid boluses in anticipation of blood loss in a normovolemic patient is inappropriate and may lead to hypervolemia.",
"   </p>",
"   <p>",
"    Although most studies evaluating goal-directed therapy have used stroke volume to optimize intravascular volume, the optimal monitoring scheme is unknown. Measures of tissue perfusion or tissue oxygenation may be superior end points. Furthermore, many questions remain unanswered such as which patients would benefit from goal-directed therapy, timing of its use (preoperative versus intraoperative), which outcome measures or endpoints are optimal, what therapy constitutes the best approach to achieve the target (eg, fluids, vasopressors, or inotropic agents), and how long in the postoperative period the regimen should be maintained. (See",
"    <a class=\"local\" href=\"#H254311231\">",
"     'Monitoring volume status'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626508236\">",
"    <span class=\"h2\">",
"     Choosing a strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized trials have found significant improvements in length of stay, earlier return of bowel function and decreased complications (eg, pneumonia) using restrictive or goal-directed fluid therapy compared with fixed-volume regimens, mortality reductions are not consistently demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/28,29,33,34,69,70,74,76,77\">",
"     28,29,33,34,69,70,74,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limitations of the available studies comparing the various fluid strategies include insufficient study design, small sample size, lack of control group, and lack of well-defined endpoints (ie, specific complication or group of complications related to fluid therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, there is limited information regarding anesthetic technique and surgical care.",
"   </p>",
"   <p>",
"    We primarily base intraoperative fluid management on the invasiveness of the surgical procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing minimal to moderately invasive surgical procedures that are not associated with significant fluid shifts or blood loss (eg, surgical procedures generally performed on an outpatient basis), volume replacement with a balanced electrolyte solution (eg, Ringer&rsquo;s lactate solution) alone is usually adequate. A baseline crystalloid infusion of 1 to 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour with crystalloid boluses (20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      as needed, has been found in randomized trials to reduce the surgical stress response, lower the incidence of postoperative nausea and vomiting, and shorten hospital stay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/31,78,79\">",
"       31,78,79",
"      </a>",
"      ]. Smaller fluid boluses are used in patients with a history of heart failure. &nbsp;",
"     </li>",
"     <li>",
"      For major surgical procedures with significant fluid shifts and blood pressure lability, larger volumes of crystalloids may be detrimental and it is preferable to use an approach that combines crystalloids and colloids with a goal of limiting the amount of fluid administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/2,6,12\">",
"       2,6,12",
"      </a>",
"      ]. We use a fluid restricted approach or goal-directed fluid therapy. The use of dynamic parameters to guide fluid therapy is ideal. (See",
"      <a class=\"local\" href=\"#H626508215\">",
"       'Restrictive fluid therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H626508222\">",
"       'Goal-directed fluid therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Crystalloids are used to replace sensible and insensible losses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/46/42729/abstract/2\">",
"       2",
"      </a>",
"      ]. Balanced electrolyte solutions (eg, Ringer&rsquo;s lactate) are preferred.",
"     </li>",
"     <li>",
"      Colloids should be used to replace blood loss (volume to volume basis) due to their superior intravascular volume effect until blood is indicated and available for transfusion. In addition, colloids improve tissue perfusion and hydroxyethyl starch solutions reduce blood viscosity, which may improve microvascular circulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058523279\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of fluid status (both under- and overhydration) can adversely influence organ function and thus influence operative outcome. The main goal of intraoperative fluid therapy is to maintain tissue perfusion by optimizing intravascular volume status and stroke volume and avoiding extravascular fluid overload. Attention to volume status and fluid therapy should include the entire perioperative period (ie, preoperative, intraoperative, and postoperative periods). (See",
"      <a class=\"local\" href=\"#H254312679\">",
"       'Intraoperative changes in volume and tissue perfusion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H254314205\">",
"       'Factors affecting volume status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are undergoing mild to moderately invasive procedures (eg, outpatient surgical procedures), we suggest a baseline crystalloid infusion of 1 to 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour with crystalloid boluses (20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      as needed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Smaller fluid boluses are used in patients with a history of heart failure. (See",
"      <a class=\"local\" href=\"#H254311346\">",
"       'Fluid strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For major surgical procedures, we suggest a fluid restricted or goal-directed fluid approach over a fixed-volume regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The traditional practice of fixed volume fluid administration should be abandoned. Crystalloid (0.5 to 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) may be administered to replace sensible and insensible losses and colloid used to replace blood loss. Alternatively, dynamic parameters may be used to guide volume replacement. (See",
"      <a class=\"local\" href=\"#H254311346\">",
"       'Fluid strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The parameters used to monitor intravascular volume depend upon available equipment and may use &lsquo;static&rsquo; measures including heart rate, arterial blood pressure, and central venous pressures or &lsquo;dynamic&rsquo; flow-related variables such as stroke volume or systolic or pulse pressure variation. Dynamic indices are superior for detecting volume responsiveness and guiding goal-directed fluid therapy. (See",
"      <a class=\"local\" href=\"#H254311231\">",
"       'Monitoring volume status'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/1\">",
"      Joshi GP. Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery. Anesth Analg 2005; 101:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/2\">",
"      Chappell D, Jacob M, Hofmann-Kiefer K, et al. A rational approach to perioperative fluid management. Anesthesiology 2008; 109:723.",
"     </a>",
"    </li>",
"    <li>",
"     British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients (GIFTASUP). London: NHS National Library of Health. file://www.ics.ac.uk/intensive_care_professional/standards_and_guidelines/british_consensus_guidelines_on_intravenous_fluid_therapy_for_adult_surgical_patients__giftasup__2008 (Accessed on September 18, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/4\">",
"      Chawla G, Drummond GB. Textbook coverage of a common topic: fluid management of patients after surgery. Med Educ 2008; 42:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/5\">",
"      Soni N. British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients (GIFTASUP): Cassandra's view. Anaesthesia 2009; 64:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/6\">",
"      Brandstrup B. Fluid therapy for the surgical patient. Best Pract Res Clin Anaesthesiol 2006; 20:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/7\">",
"      Kheterpal S, Tremper KK, Englesbe MJ, et al. Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology 2007; 107:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/8\">",
"      Chieveley-Williams S, Hamilton-Davies C. The role of the gut in major surgical postoperative morbidity. Int Anesthesiol Clin 1999; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/9\">",
"      Lowell JA, Schifferdecker C, Driscoll DF, et al. Postoperative fluid overload: not a benign problem. Crit Care Med 1990; 18:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/10\">",
"      Holte K, Sharrock NE, Kehlet H. Pathophysiology and clinical implications of perioperative fluid excess. Br J Anaesth 2002; 89:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/11\">",
"      Arieff AI. Fatal postoperative pulmonary edema: pathogenesis and literature review. Chest 1999; 115:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/12\">",
"      Nisanevich V, Felsenstein I, Almogy G, et al. Effect of intraoperative fluid management on outcome after intraabdominal surgery. Anesthesiology 2005; 103:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/13\">",
"      Mayberry JC, Welker KJ, Goldman RK, Mullins RJ. Mechanism of acute ascites formation after trauma resuscitation. Arch Surg 2003; 138:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/14\">",
"      Balogh Z, McKinley BA, Cocanour CS, et al. Supranormal trauma resuscitation causes more cases of abdominal compartment syndrome. Arch Surg 2003; 138:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/15\">",
"      Jacob M, Chappell D, Conzen P, et al. Blood volume is normal after pre-operative overnight fasting. Acta Anaesthesiol Scand 2008; 52:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/16\">",
"      Brauer KI, Svens&eacute;n C, Hahn RG, et al. Volume kinetic analysis of the distribution of 0.9% saline in conscious versus isoflurane-anesthetized sheep. Anesthesiology 2002; 96:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/17\">",
"      Connolly CM, Kramer GC, Hahn RG, et al. Isoflurane but not mechanical ventilation promotes extravascular fluid accumulation during crystalloid volume loading. Anesthesiology 2003; 98:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/18\">",
"      Jacob M, Chappell D, Rehm M. The 'third space'--fact or fiction? Best Pract Res Clin Anaesthesiol 2009; 23:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/19\">",
"      Lamke LO, Nilsson GE, Reithner HL. Water loss by evaporation from the abdominal cavity during surgery. Acta Chir Scand 1977; 143:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/20\">",
"      Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/21\">",
"      Magder S. Fluid status and fluid responsiveness. Curr Opin Crit Care 2010; 16:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/22\">",
"      Alpert RA, Roizen MF, Hamilton WK, et al. Intraoperative urinary output does not predict postoperative renal function in patients undergoing abdominal aortic revascularization. Surgery 1984; 95:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/23\">",
"      Renner J, Scholz J, Bein B. Monitoring fluid therapy. Best Pract Res Clin Anaesthesiol 2009; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/24\">",
"      Knotzer H, Hasibeder WR. Microcirculatory function monitoring at the bedside--a view from the intensive care. Physiol Meas 2007; 28:R65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/25\">",
"      Funk DJ, Moretti EW, Gan TJ. Minimally invasive cardiac output monitoring in the perioperative setting. Anesth Analg 2009; 108:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/26\">",
"      Desebbe O, Cannesson M. Using ventilation-induced plethysmographic variations to optimize patient fluid status. Curr Opin Anaesthesiol 2008; 21:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/27\">",
"      Cecconi M, Parsons AK, Rhodes A. What is a fluid challenge? Curr Opin Crit Care 2011; 17:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/28\">",
"      Abbas SM, Hill AG. Systematic review of the literature for the use of oesophageal Doppler monitor for fluid replacement in major abdominal surgery. Anaesthesia 2008; 63:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/29\">",
"      Phan TD, Ismail H, Heriot AG, Ho KM. Improving perioperative outcomes: fluid optimization with the esophageal Doppler monitor, a metaanalysis and review. J Am Coll Surg 2008; 207:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/30\">",
"      Bundgaard-Nielsen M, Holte K, Secher NH, Kehlet H. Monitoring of peri-operative fluid administration by individualized goal-directed therapy. Acta Anaesthesiol Scand 2007; 51:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/31\">",
"      Bundgaard-Nielsen M, Secher NH, Kehlet H. 'Liberal' vs. 'restrictive' perioperative fluid therapy--a critical assessment of the evidence. Acta Anaesthesiol Scand 2009; 53:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/32\">",
"      Walsh SR, Tang T, Bass S, Gaunt ME. Doppler-guided intra-operative fluid management during major abdominal surgery: systematic review and meta-analysis. Int J Clin Pract 2008; 62:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/33\">",
"      Kuper M, Gold SJ, Callow C, et al. Intraoperative fluid management guided by oesophageal Doppler monitoring. BMJ 2011; 342:d3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/34\">",
"      Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg 2011; 112:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/35\">",
"      Campbell B. Innovation, NICE, and CardioQ. Br J Anaesth 2012; 108:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/36\">",
"      Yin JY, Ho KM. Use of plethysmographic variability index derived from the Massimo(&reg;) pulse oximeter to predict fluid or preload responsiveness: a systematic review and meta-analysis. Anaesthesia 2012; 67:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/37\">",
"      Doherty M, Buggy DJ. Intraoperative fluids: how much is too much? Br J Anaesth 2012; 109:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/38\">",
"      Cannesson M, Le Manach Y, Hofer CK, et al. Assessing the diagnostic accuracy of pulse pressure variations for the prediction of fluid responsiveness: a \"gray zone\" approach. Anesthesiology 2011; 115:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/39\">",
"      Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med 2009; 37:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/40\">",
"      Thiele RH, Colquhoun DA, Blum FE, Durieux ME. The ability of anesthesia providers to visually estimate systolic pressure variability using the \"eyeball\" technique. Anesth Analg 2012; 115:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/41\">",
"      Michard F, Biais M. Rational fluid management: dissecting facts from fiction. Br J Anaesth 2012; 108:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/42\">",
"      Lansdorp B, Lemson J, van Putten MJ, et al. Dynamic indices do not predict volume responsiveness in routine clinical practice. Br J Anaesth 2012; 108:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/43\">",
"      Ertmer C, Rehberg S, Van Aken H, Westphal M. Relevance of non-albumin colloids in intensive care medicine. Best Pract Res Clin Anaesthesiol 2009; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/44\">",
"      Hahn RG. Volume kinetics for infusion fluids. Anesthesiology 2010; 113:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/45\">",
"      Hiltebrand LB, Kimberger O, Arnberger M, et al. Crystalloids versus colloids for goal-directed fluid therapy in major surgery. Crit Care 2009; 13:R40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/46\">",
"      McIlroy DR, Kharasch ED. Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia. Anesth Analg 2003; 96:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/47\">",
"      Scheingraber S, Rehm M, Sehmisch C, Finsterer U. Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery. Anesthesiology 1999; 90:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/48\">",
"      Wilkes NJ, Woolf R, Mutch M, et al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg 2001; 93:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/49\">",
"      Healey MA, Davis RE, Liu FC, et al. Lactated ringer's is superior to normal saline in a model of massive hemorrhage and resuscitation. J Trauma 1998; 45:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/50\">",
"      Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte&reg; 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/51\">",
"      Shaw AD, Bagshaw SM, Goldstein SL, et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg 2012; 255:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/52\">",
"      Sch&auml;fer M, Von Ungern-Sternberg BS, Wight E, Schneider MC. Isotonic fluid absorption during hysteroscopy resulting in severe hyperchloremic acidosis. Anesthesiology 2005; 103:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/53\">",
"      Gheorghe C, Dadu R, Blot C, et al. Hyperchloremic metabolic acidosis following resuscitation of shock. Chest 2010; 138:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/54\">",
"      Westphal M, James MF, Kozek-Langenecker S, et al. Hydroxyethyl starches: different products--different effects. Anesthesiology 2009; 111:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/55\">",
"      Van Der Linden P, James M, Mythen M, Weiskopf RB. Safety of modern starches used during surgery. Anesth Analg 2013; 116:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/56\">",
"      Zarychanski R, Turgeon AF, Fergusson DA, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials: ATTENTION: The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release. Open Med 2009; 3:e196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/57\">",
"      Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/58\">",
"      Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010; :CD007594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/59\">",
"      Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology 2005; 103:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/60\">",
"      Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008; 107:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/61\">",
"      Thomas-Rueddel DO, Vlasakov V, Reinhart K, et al. Safety of gelatin for volume resuscitation--a systematic review and meta-analysis. Intensive Care Med 2012; 38:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/62\">",
"      Groeneveld AB, Navickis RJ, Wilkes MM. Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg 2011; 253:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/63\">",
"      Lassen K. Intravenous fluid therapy. Br J Surg 2009; 96:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/64\">",
"      Lobo DN. Fluid overload and surgical outcome: another piece in the jigsaw. Ann Surg 2009; 249:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/65\">",
"      Bellomo R. Noradrenaline: friend or foe? Heart Lung Circ 2003; 12 Suppl 2:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/66\">",
"      Sear JW. Kidney dysfunction in the postoperative period. Br J Anaesth 2005; 95:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/67\">",
"      Rahbari NN, Zimmermann JB, Schmidt T, et al. Meta-analysis of standard, restrictive and supplemental fluid administration in colorectal surgery. Br J Surg 2009; 96:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/68\">",
"      Lobo SM, Ronchi LS, Oliveira NE, et al. Restrictive strategy of intraoperative fluid maintenance during optimization of oxygen delivery decreases major complications after high-risk surgery. Crit Care 2011; 15:R226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/69\">",
"      Abraham-Nordling M, Hjern F, Pollack J, et al. Randomized clinical trial of fluid restriction in colorectal surgery. Br J Surg 2012; 99:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/70\">",
"      Corcoran T, Rhodes JE, Clarke S, et al. Perioperative fluid management strategies in major surgery: a stratified meta-analysis. Anesth Analg 2012; 114:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/71\">",
"      Kimberger O, Arnberger M, Brandt S, et al. Goal-directed colloid administration improves the microcirculation of healthy and perianastomotic colon. Anesthesiology 2009; 110:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/72\">",
"      Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/73\">",
"      Kehlet H, Bundgaard-Nielsen M. Goal-directed perioperative fluid management: why, when, and how? Anesthesiology 2009; 110:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/74\">",
"      Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. Br J Anaesth 2009; 103:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/75\">",
"      Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. Br J Surg 2006; 93:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/76\">",
"      Gurgel ST, do Nascimento P Jr. Maintaining tissue perfusion in high-risk surgical patients: a systematic review of randomized clinical trials. Anesth Analg 2011; 112:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/77\">",
"      Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 2011; 112:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/78\">",
"      Lambert KG, Wakim JH, Lambert NE. Preoperative fluid bolus and reduction of postoperative nausea and vomiting in patients undergoing laparoscopic gynecologic surgery. AANA J 2009; 77:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/46/42729/abstract/79\">",
"      Maharaj CH, Kallam SR, Malik A, et al. Preoperative intravenous fluid therapy decreases postoperative nausea and pain in high risk patients. Anesth Analg 2005; 100:675.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14942 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42729=[""].join("\n");
var outline_f41_46_42729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1058523279\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058520434\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H254312679\">",
"      INTRAOPERATIVE CHANGES IN VOLUME AND TISSUE PERFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694830816\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254314149\">",
"      Hypovolemia and reduced tissue perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254314156\">",
"      Hypervolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H254314205\">",
"      FACTORS AFFECTING VOLUME STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H254311231\">",
"      MONITORING VOLUME STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H787888996\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254311286\">",
"      Dynamic parameters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15026173\">",
"      - Stroke volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15026180\">",
"      - Respiratory variation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15026187\">",
"      - Monitoring the microcirculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058523188\">",
"      FLUID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4057778\">",
"      Crystalloid solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4057785\">",
"      Hydroxyethyl starches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35630849\">",
"      - Terminology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35630868\">",
"      - Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4057814\">",
"      Plasma and plasma derivatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4057821\">",
"      Blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4057828\">",
"      Gelatins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4057835\">",
"      Dextrans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H254311346\">",
"      FLUID STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626508208\">",
"      Fixed volume therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626508215\">",
"      Restrictive fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626508222\">",
"      Goal-directed fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626508236\">",
"      Choosing a strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058523279\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14942|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/12/194\" title=\"figure 1\">",
"      Systolic pressure variation and pulse pressure variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/34/22051\" title=\"figure 2\">",
"      Volume responsiveness to guide fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/32/21003\" title=\"table 1\">",
"      Dynamic parameters for intraoperative fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/17/18717\" title=\"table 2\">",
"      Crystalloids and colloids for plasma expansion in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24073?source=related_link\">",
"      Oxygen carriers as alternatives to red cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5177?source=related_link\">",
"      Wound healing and risk factors for non-healing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_46_42730="RVH tutorial";
var content_f41_46_42730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1261px;\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Right ventricular hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right ventricular forces become predominant in patients with right ventricular hypertrophy (RVH), producing tall R waves in the right precordial leads (V1 and V2), and deep S waves in the left precordial leads (V5 and V6); a R:S ratio &gt;1 in V1 and V2 is suggestive of RVH. Other features in this case include right axis deviation and RV1 &gt;7 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42730=[""].join("\n");
var outline_f41_46_42730=null;
var title_f41_46_42731="Reg nodes colorec CA";
var content_f41_46_42731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The regional lymph nodes for each segment of the large bowel",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Segment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regional lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cecum",
"       </td>",
"       <td>",
"        Pericolic, anterior cecal, posterior cecal, ileocolic, right colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending colon",
"       </td>",
"       <td>",
"        Pericolic, ileocolic, right colic, middle colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic flexure",
"       </td>",
"       <td>",
"        Pericolic, middle colic, right colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse colon",
"       </td>",
"       <td>",
"        Pericolic, middle colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenic flexure",
"       </td>",
"       <td>",
"        Pericolic, middle colic, left colic, inferior mesenteric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Descending colon",
"       </td>",
"       <td>",
"        Pericolic, left colic, inferior mesenteric, sigmoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sigmoid colon",
"       </td>",
"       <td>",
"        Pericolic, inferior mesenteric, superior rectal (hemorrhoidal), sigmoidal, sigmoid mesenteric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectosigmoid",
"       </td>",
"       <td>",
"        Pericolic, perirectal, left colic, sigmoid mesenteric, sigmoidal, inferior mesenteric, superior rectal (hemorrhoidal), middle rectal (hemorrhoidal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectum",
"       </td>",
"       <td>",
"        Perirectal, sigmoid mesenteric, inferior mesenteric, lateral sacral presacral, internal iliac, sacral promontory, internal iliac, superior rectal (hemorrhoidal), middle rectal (hemorrhoidal), inferior rectal (hemorrhoidal)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42731=[""].join("\n");
var outline_f41_46_42731=null;
var title_f41_46_42732="Risk strat system advancted TGCTs";
var content_f41_46_42732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk stratification system for advanced testicular germ cell tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Seminomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Good risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         All of the following:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any primary site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No metastases to organs other than the lungs and/or lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal serum AFP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         All of the following:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any primary site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastases to organs other than the lungs and/or lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal serum AFP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-seminomatous germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Good risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         All of the following:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Testicular or retroperitoneal primary tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No metastases to organs other than the lungs and/or lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum AFP &lt;1000 ng/mL, beta-hCG &lt;5000 mIU/mL, and LDH &lt;1.5 times upper limit of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         All of the following:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Testicular or retroperitoneal primary tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No metastases to organs other than the lungs and/or lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum AFP 1000 to 10,000 mg/mL",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum beta-hCG 5000 to 50,000 mIU/mL",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LDH 1.5 to 10 times upper limit of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Poor risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Any of the following:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mediastinal primary with or without metastases, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastases to organs other than the lungs and/or lymph nodes, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum AFP &gt;10,000 ng/mL, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum beta-hCG &gt;50,000 mIU/mL, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LDH more than 10 times upper limit of normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein beta-hCG: beta-human chorionic gonadotropin LDH: lactic dehydrogenase.",
"    </div>",
"    <div class=\"reference\">",
"     Based upon the guidelines of the International Germ Cell Cancer collaborative group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42732=[""].join("\n");
var outline_f41_46_42732=null;
var title_f41_46_42733="Nutrition needs preterm inf";
var content_f41_46_42733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of parenteral and enteral fluid, energy, and nutrient intakes for stable, growing premature infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Component, units",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Unit/kg/day (except as noted)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Parenteral",
"       </td>",
"       <td class=\"subtitle2\">",
"        Enteral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water, mL",
"       </td>",
"       <td>",
"        120 to 160",
"       </td>",
"       <td>",
"        135 to 190",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy, kcal",
"       </td>",
"       <td>",
"        90 to 100",
"       </td>",
"       <td>",
"        110 to 130",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein, g",
"       </td>",
"       <td>",
"        3.2 to 3.8",
"       </td>",
"       <td>",
"        3.4 to 4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat, g",
"       </td>",
"       <td>",
"        3 to 4",
"       </td>",
"       <td>",
"        5.3 to 7.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate, g",
"       </td>",
"       <td>",
"        9.7 to 15",
"       </td>",
"       <td>",
"        7 to 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linoleic Acid, mg",
"       </td>",
"       <td>",
"        340 to 800",
"       </td>",
"       <td>",
"        600 to 1440",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin A, int. unit",
"       </td>",
"       <td>",
"        700 to 1500",
"       </td>",
"       <td>",
"        700 to 1500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D,&nbsp;int. unit&nbsp;",
"       </td>",
"       <td>",
"        40 to 160",
"       </td>",
"       <td>",
"        150 to 400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin E,&nbsp;int. unit&nbsp;",
"       </td>",
"       <td>",
"        2.8 to 3.5",
"       </td>",
"       <td>",
"        6 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin K*, mcg",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        8 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thiamin (vitamin B1), mcg",
"       </td>",
"       <td>",
"        200 to 350",
"       </td>",
"       <td>",
"        180 to 240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Riboflavin (vitamin B2), mcg",
"       </td>",
"       <td>",
"        150 to 200",
"       </td>",
"       <td>",
"        250 to 360",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pyridoxine (vitamin B6), mcg",
"       </td>",
"       <td>",
"        150 to 200",
"       </td>",
"       <td>",
"        150 to 210",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin B12, mcg",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Niacin, mg",
"       </td>",
"       <td>",
"        4 to 6.8",
"       </td>",
"       <td>",
"        3.6 to 4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Folic Acid, mcg",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sodium, mg",
"       </td>",
"       <td>",
"        69 to 115",
"       </td>",
"       <td>",
"        69 to 115",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Potassium, mg",
"       </td>",
"       <td>",
"        78 to 117",
"       </td>",
"       <td>",
"        78 to 117",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chloride, mg",
"       </td>",
"       <td>",
"        107 to 249",
"       </td>",
"       <td>",
"        107 to 249",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Minerals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calcium, mg",
"       </td>",
"       <td>",
"        60 to 80",
"       </td>",
"       <td>",
"        100 to 220",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phosphorus, mg",
"       </td>",
"       <td>",
"        45 to 60",
"       </td>",
"       <td>",
"        60 to 140",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Magnesium, mg",
"       </td>",
"       <td>",
"        4.3 to 7.2",
"       </td>",
"       <td>",
"        7.9 to 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Trace elements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iron, mg",
"       </td>",
"       <td>",
"        100 to 200",
"       </td>",
"       <td>",
"        2000 to 4000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Zinc, mcg",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        1000 to 3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Copper, mcg",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        120 to 150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chromium, mcg",
"       </td>",
"       <td>",
"        0.05 to 0.3",
"       </td>",
"       <td>",
"        0.1 to 2.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Manganese, mcg",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.7 to 7.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Selenium, mcg",
"       </td>",
"       <td>",
"        1.5 to 4.5",
"       </td>",
"       <td>",
"        1.3 to 4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine, mg",
"       </td>",
"       <td>",
"        &sim;3",
"       </td>",
"       <td>",
"        &sim;3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Vitamin K, 0.5&nbsp;to 1 mg given at birth.",
"     <br>",
"      <strong>",
"       The following conversion factors are used:",
"      </strong>",
"      <br>",
"       Ca: 40 mg = 1 mmoL = 2 mEq.",
"       <br>",
"        P: 31 mg = 1 mmoL.",
"        <br>",
"         Mg: 24 mg = 1 mmoL = 2 mEq.",
"         <br>",
"          Na: 23 mg = 1 mmoL = 1 mEq.",
"          <br>",
"           K: 39 mg = 1 mmoL = 1 mEq.",
"           <br>",
"            Cl: 35 mg = 1 mmoL = 1 mEq.",
"            <br>",
"             Vitamin A: 1 mcg retinol = 3.33 IU vitamin A = 6 mcg beta-carotene = 1.83 mcg retinyl palmitate = 1 retinol equivalent (RE).",
"             <br>",
"              Vitamin E: 1 mg alpha-tocopherol = 1 IU vitamin E.",
"              <br>",
"               Vitamin D: 1 mcg vitamin D (cholecalciferol) = 40 IU vitamin D (cholecalciferol).",
"               <br>",
"                Niacin: 1 mg niacin = 1 niacin equivalent (NE) = 60 mg tryptophan.",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schanler RJ, Anderson D. The Low Birth-Weight Infant: Inpatient Care. In: Nutrition in Pediatrics, 4th ed, Duggan C, Watkins JB, Walker WA (Eds), BC Decker Inc, Hamilton, Ontario, Canada 2008 Copyright &copy;2008 PMPH-USA, Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42733=[""].join("\n");
var outline_f41_46_42733=null;
var title_f41_46_42734="Kaplan-Meier survival curve metastatic well-differentiated NETs";
var content_f41_46_42734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaplan-Meier survival curve of metastatic well-differentiated neuroendocrine tumors of the digestive system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 686px; background-image: url(data:image/gif;base64,R0lGODlhMwGuAsQAAP///wAAAMzMzP8AAO7u7oiIiBEREQAzmTMzMyIiIru7u6qqqpmZmXd3d0RERFVVVd3d3WZmZkBAQEBms4CZzMDN5oCAgP9AQH8ZTAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAzAa4CAAX/YACMZGmeaKqubOu+cCzPdG3feG4Gou7/wKBwSCwaVbyjcslsOp/NJHRKrVqvSyl2y+16v9qveEwu/8LmtHrNBqDb8Lgc+p7b73hdPc/v+1NhPIKDhD1/h4hkgS6GiY6PVostjZCVlkqSJAYBBjuXn6BDmQAMggwllKGqqzKjDpwBDqistLWMjYYQPAo8ECSptsG2mQWxAAgBBb/CzMKZCYQJy83UrJK8Ab66AQojwNXgj5IRxiOvEd7h6pajSGB6Od+t8fQ48jH3L/kz7YDv9Tf2MQJoQyALgwcJ6sE10AvCFQ/9KaQREUXFExcxTrSHq5DHjEVAzrIHj6TJgCVR/wLZA0fkNJUnC26cNxNfEJZt9umclJAnRJ/uegb9SbToUIlGF/LZKfSoxYZOnyaVGlXjVKtXR2Yt6HIL060vkYJ1A1SsWaxVtaZVS3VtDZxjPsqdS7eu3bt48+rdy7evX7wBuz4RvE6VSLhiCBcGdVhxjQUPHS9mF9gKtMiTM4flJ3kGL5uaMze+8hlG59CIRlspbcKC3BMDYsueTbt2bdQ/GvAwoMwEgVcBECwYIQBZLF+kNgVAB0AAoQc7Pkq4RRrzjQMpBuDWUQwdsuElXjEgYMAAAQIJDECAjAAAr/a6GzTnQeAsvtMxWEOtgR2FdtS6IQBNAsiRUAwh8pUAzf9w3ZWwTX3ildIeAJtAQI58vEjjXAD1tcWZZYLIsh8NFWSHW4AAFCNiDJsIkGI5xHEywgPJFAMdhdzQqIxznWzIgwMFpsNVHPj9F5pu0PE4Q4svrjhfJwDoaOMImyig45Mm0OgkWUO2RISRmiHpnowlHDhIgiQs+CJzIzwIQITBUZnNhWNKUwJkdm7WCn4hfXliANCRc2MMDX53TADDiQdBefWVB4GEY7ZHZwHM0YimkG/xSYRLB3R6QIkjHDBAp6AC4OmnJJxa6iq6XeZAhzLoxklvhv7Gg3DEGQfkCAwox5wAyiWD1odeDgFmZmLaoVpOfgII6B3LslEkDf1t51X/ZcUKcewL1Vp7RbRrTDtDt95WAS4ZrgnSrAzkljvFINPtSeS6MZSqaqqe2psvvqTyi2qo+wLcr8D/mhrwKuemIa6783bJrLEMy5GwGQuv0u4lE5dRsSoXU+awtPRybA22D2tbS8eVZKxIyKGsyhjJU8iaQDcj/hBbxNlSpCkLvfrSAJRlBbEtzhrDzMJ5SCN9AwMJ1LdAnk0JffLBpyai8p0fgVcDOREg4GLNNq/jch9XkwCZR1p7RiADCAw6QroeFTE00XFJR90LSSd9wwO96RKkWzjMTfc/mcpAQAENJN7A34wo0wCBKZoHtg+CD95F2VkSkrY+yhBAYwAz6yO3/22y2YIytEa3YICADvz8dRRTVG7J6cqmvgIBiDoAHa5O7GziyVbbrgLuDPxs/GCxmx78xy607ePmmCRfy9hLCd/CAg1AHz0UslvOBOYlPBDB63RI730k1qegawGwws79baHQLnH6KTDwwCYG0Oz+Fd0fIn/DhZuBAA6kPSP4zgX9+8P/ckYsGBTAOMdZAtwO2IIE+mGBORFEvO4jA2QkoAHk258VLNgH6uEBfAY6hbm2QMLzpURnMOhQ3sqHhRa6MCYNZAFkFgBBHhSwTzW82Q23F8DrIaqHiEIeF2xoBwyCjHm3G8EMlchCUBwsDyic0fhWuMQhEhGGMVhf+77XBf8m8sGJK4NiC+yHP/3RwHM86E3QRkgLNMaFfikYoA9vgIBXgaaKrLBjYvBoggeGiHEwWADQTFPGOlZPjSvwIAhx8DhTiG6JpLOECRkoL0KpMAdd4xWHSjBBQqTBjF60iN0mEREFuPEGBRgUNybXyFS+MIcucMCECqIMXnSjAJKb4xdQaUu2dDKRCNAbP3pzoNDRsouVECThwAgDJP5wU6ecXadOSMgSWJOKZCBmGzYZrm6WYIq9O6VtikmTIr7gm+mMgzhdmMVDDeKaopDDPM9XTwAgDViINKA+EyFNLvQTabyQIxnlSVBuQlIFSFRoFgaKiIJe66HqG4Qf4wmHfX7/waJYOKjSmDBBih6CnGqAFy5dUB8C4BObDGUnIzGKAgcAaRO7FCEbPCqGe5WMmiytUXAC8MmFdlSmM3VnC3C3AHIoAAGXmmhMkSpM00QkAQ6ABgGgCs6dUvWZrIwVDx6gi6JK9aiz4yQHZVAA9mFvjF/0alp/ulKF6ZOnZABpV49ZhWIEdFhyhYReOQrUKSgyG5ec6iNQOs26NsE5kPmrJ0z6VftY9QZwjQEEErAAvyUWrZW1rD5AYqgaIEAZniXlayj7CE+Fa5UHIW0SMzUIs4rWDKWbaw2eKogtAmBRr4RJYfE20lYoNLVVXQNeycBYFTgnQQJwwCnIMUsf1BOY//dcpoMQC1bcTsYBbMJIcGVC0xMEa4+EVaw6DPDD6t6Sry4wwAOUmV7QroO9v7WkN8b7FnOOoAHzLa5O7dtaG4AXFZ90b03u5kDN7bUNyx1DQXnBHOL9gr8U8S+OsltfCF/CorzlwRapi5jPOlYF8qXvgCFMuhbPYbBxhW8LAKxio1oiwktobkg1DM8VOwLH1Khnj21cCSA3Q6QCJjIkjMwMJJ+HpIMAhZFDvBwBwJETtoWBTw02MC4XbMtgptoVo8ODDV42jA7u8I+J8FziSBcCXgOAbjym1BYM+aw3JsKBVaAAqDkCyQB98JqHgF8VRECyZNOwP8+TUEEngjZAwP/vNohqoBD+mceEkGiML4HXPXtDhQ54aaLLa4IebtTHRQYChaVIVDhrWhyKrrGSOR0EKo8PG/qFNalHgD2tJY6GqmAyLVCIgGDKWcEyKM6tLH3bRwh7ZLvGXXh1EdUY2K8+fTTxJ56NsG7i7lLf5k54xzJoy6EwAU0zkLBw4LmkhoLbhjFnqyLQgFcY2wbzPUEpo7yKFvv73wAP+AVOCFuIPITEWMYBnBE92dD+oZ4KSBz73tJLAzCb3A5X65l7pwwz9aK7GaerjO0a8lHXmeQlx6Kiv5XyR56cYi1X+a4vF3OHvrxoNa/dzA2ac53fPI09B+Bwx1DSoBNJgycGutH/n/jzOy5d5GuF+tOVnnSnTz2lK0ff1bG+84tuHeZd3/HXwd70QY4d52U3woEQwHBMnd3saWdzAFz0ALdh/O3vyjp3RKSARd4d745mMBQiwBxdZBawgBd73IdA+DaNkgT7VlfiHVJwJFAQBQUQkSK1PXmtL14IzqG73QHXeTWP1gprbzuXSq/4oZOd9Z53Pdphz8XPe532VOgny3Ffe9kr4i/AD77wh0/84hvfLnqnedQ8xPyGj+UrzV599PMB/WZXPx6XByK5r+98wHHfmIgHf/fDL/7yuz36Ixf69JN7fuuzX/ruX/74ya+n+ds/7HBXgZmjv3/6k6D/9/d/8mcC/wBofiNQgPVHgO+HgAmIf43VXzgEgcIlgeQVgfxwE9kHUxbYThOYYRv4Rx14gSuRgfm0YJwngiHIgRRYgSyoFDL3ge7Wgh6YgiAogyhoXSQoBAwIAzvoAj3ogznwgywghCtAhEUYhBjIezJVYkpINEzYhBHzhFDoLlI4hd5ShVa4HVjoBX3HCRhWP67SIcCxJSyQVSQwhjCgbNWFhksFHGxnDj/CAsBFAl2YPyNQh+M1h/70OQagQniYAnpIh5TmHm2EAoH4IuXwh76nBrwROTIQAajViAXQNOjxaijwM3YyieeRAJZoAotyKZpYiS0QSscAHaHIiYa2C5rQcVAiif9+BwDURTNw5iJzRiGsiAKx6CDloUKueAK5+F9xtoqOuIhm4By/cHEtIF1Rwkyjh3mcaCd8MwKx5AIAliXMOIo30gDoEI0p0oyoQDPG6A0CEI5uwGzI5h4aYghzBwj6U4kJcArkuI7ixWrkE4/IaHB3wDRpImonMEAj8I68klMp0HePYicASQoCqT6XkQAucpBss1TFFgF+5JAJuQM0o4//uAAYCQCcZRHBdWikkCcd6ZFnKB8AuZEjaZG8BjoiFpL7SIxlgJL86CBsQpFyaIcYaZMt8EEjEEo6uQKZlyKo+JPsyCsiqZFHSZJl8jUyWZRyJiInmZTzmBy+ACxI+ZL/VVeMPYA794gCCuAk3FiNK4BrggABYemNJuAAvfEZZ6k6FykNbQkR4LiVcxeOXKmU5qA1dimPUwkcvbWX5kgzfXeGBQCYMFkGvUgo6WYglIiKL4CRp9iJZQI5DyALkWlnImJTQrmJkukG+pOYiTmVrmYCoTmVCsKLt6iU5LEjs1SaUTcHiggDfgk6cAgjLrCRbOgCn/OGbxKHLaCGvJmbuMhvihibJIBwY1JbhOiFwyl5aeKHhWgCyImOcXSH0ZmVWUiFOZidGLOd3Jky3vmd4hCe4mk15Fmeh7CF6LkO6rme4dCe7lkN8BmfR3ae9Elw98kw85mfw2Cf/Ckx/vmf/y0RoAIqLQSaSrjDl9q5dJ8DHsjwiiyADJ3DA12pGfs5RLtJCrvRQcKSoBUqGgdaDTSCDEyDP9IoCAmCDA+ADMn0OfTBAz/zLIhIJiDKoAHQAMZRDJ0gJnSCDPIhoYcyoYhCHtxQDBW5GBd6Q5YCGQ8AGZ0ADaeAJ0EaJTc6pR6KIxp5K5NkoSFKDZZiNjICpQAgpUD6pUB6pZvAICSmesGQpC70pSu5o8/So8Lypa8gpC6SpiSwDWzanzaKJk56ojA6AmVapYfFIRSKpbICOlmmDm5aoJ/wqJDKDl06qXVjqaEhqZj6Z5W6qZfTqZ7qFaAaqt8yqqRqLqZ6qu9Sl//j2Kqu+qqwGquyOqu0Wqu2equ4mqu6uqu82qu++qvAGqzC6qqaqqpLkarG2jvImqzfs6zMigkdgXzPap4G2H7TeqzVCn/Xiq0vYWoF4qzbGlbdmkRwqq27V4LoKgR8gh/rmoTjOhw0kmAPeAbap671uhL3in1aYWqvc6DtqoH2CrD4KrD6+q5jSpvWGns3ka/0SrDWxbAwYwi18nHmqrADm64L67Dv1bBnwBCEmkSlkCf+2nzWCgwma1knS34pO3/f0LLMJw8rC34u23ySkQne2oC5R7LmGrMJOLMsWxU8m7A+a0wwS7MkO7Q4C1QCMbIqa7Thh7QlC7RO+7QvK7X/iAe1UTuC2Rqex9e1Xvu1YBu2wBexIAex0xotgNF74Vqxp2cFkFGD4ap7P3AZcLutcvsD+vF+yXq3PpC3A3i2yacDfgsAkfcGFIABnTIBJEABnqK4QScrjegbbggeargrydGSggihcvGDxZof1mEC8IYzDBBqa3IomyMe5GEe6KEe7BEpx5YgyqG5gZsDg1sV3UMBCPojg0oCBBCjkKMmDbKn9NGbDAApOGIhVZohJKAk/hdbIOKbwtQ9MFYYCboA6DFLoztWWsMkKlICzCslMlolV8K8WNK8+KhW0pu766gjCfp4mrCO3bu8ZAK+NyK+wkK+5Jutlqd+I5C+XnSl/3dKCsDRpGmSRMHreKMEJxNSIXSivDEiuw6otv3bAo47RB66KHzZu5sAOYWSRIaiKIxCIeoBKe8Bi1X6wDoreOUEGyWXoNDQhygwuuABubSSRLYSHJSrK8jRK5i7YbubtM6Lvi/AuInrPVfKdbbXeiSASrhLNEeMcoepfKBrA9N7dnybdyzMH/F5xcBWAqhUxWPHxRLEb1NcAxWMniqVfrO3xEJkrGJseqHLem+ManFcenM8axM8A028nneMZ2XMLkVcnn28aXnsxrPraHXceYN8BPKQyJO3yDAgM19YfsS0x98JybepHnIGoTpLTGA8dSiUN0kmA0zjNH62Fp6Mxv/ddDaFMJPD2TUfyraefMbZCT6snGY00GeP0jatsVr+waybq8K3I8qH9wLciFxb4ciJV0+HoziLo12P4wvAVMyUnAOWnIX15KLohQ+d8znOlFzz9MlGV0+rg1Wug8g5IM5Bl0VMpTvH4MobW8hULJ7sTFTGYwDVxsgqME+0bIVC9gDPg857m3W91sV/rKrZ7FtY/MsD3XViZNBenAMTsE21rGhsxJxw7APqXHO6p0ezRcc+0M9NeF0QZLlHUHQM7cZIp8YZ9UGxnLH+0cakel2NisdLbMgzJ0OyRsg3jQPXDIW2fES4bNPyrMUVvWs7dGc8XdTUwp2hLEU7rc8rEM7/Is17Cf3SAbvPQPDTtCdkPzJxgQcAeLXRIddPF22HNnBlnZm0Yz2FHU1AfHRqYNXWQK1hhvQjfWoCm6eCWRzSbo1pLk1JlzGI76fMb0fTPkCKpdA+hZsPhm3FlQcIrTTJDiRLlM22TL2p9aRL9tBLszTNcw0EEx3IAEDEZJ1K9cRDUX0QzMQD3/y3mU0EVb11Xs1hqBbbllrbggDPJvjYYRxrq222uD2pur3NRC3WTcDVX1fcH33coXvaXgRommx6wx0E0D1ESNZo1I3cTHDdN8Tcaw3Tv7MEs311xS3XftzXye3dg+NkTYDS4+0E7E03afyaeONPvB3PbFzH8+2E/xpmUxh8pAJVQU9Q3uvsX7jTVkNV0xp70JqN4IjiVFy13dX9n/WEVVo14bfd06FaT7JCVoR93BUeBMq9dP3UVi7VANSMsfG9BP2NM5jc4BEt3wdQwURs4oeMA351gg5OBS+OGjHuAoelegLh2yNg4BkX5CwAWdylt9zd4cm34nLIWciMcUYOynpXWjRwWvn1N42NQAF35aEVzOK65c29J8rp5C8gbCVecroX3EhwXE0O2zIgbD+eqXZ9Xry9bo5H5GFjBHduoRp2Xme+1HV+BDW+uI2r6JVFzgH2ZGEdA1ce6MOgYTQ2yoYu6VtA6bVwXUOd3jZw5UhOT4P+6ZkOA/9i3uiD/uhSntU5kOpf5eGsDtGhHnK29jWH6OrY6U2mLtU6cOVtDglt1hzK+IsyXubv1OsD/uubTgueZposbt8sBec/AN+BI9NTwOlUUGh4KQorLe1LRe26/upXkOgjYNo2vujnru5wIGm5do4XG8Ufa9sifuiV9eyEDe8cK+/2tNuRbu9ftWr+lO+XbYMbF0PnEWgUDvABD0EjRsbjDu5Hw2h8Xu+angfB7qiYNgjhHe/Mngfazr8SD1Ea1eoeT+4gby3uTes3AOtGjRsoVND/lc9paBzBqOaozgejDg7EZmy6UfAxnG/ZVrY57wforuikffTrnvTsrvSl3fRQz/T/Um/uT0/aMcjS57Qc20XzbDVupMfwguxtJ8xqXB9DaGm+F8/H5oRusFIMHb8C+dbLHyE061TLka1KkQw69GZvJg+IvMnjfz52GY/2kh0DCAfD2tV3WI3ZlPN2dgRxEtf3O9BxhNB2vuPymfH4Ob7hHz92mh/BOXsEmD8ZO6+/ha9xQDD63qPk4s0yI735Ft/yTg37oC41Zzf4AYjsK2wEql8Yn5/E5yo3jn+Duy7Fwn92VA/4uo8uEP8lYa7I337wu88/ikz7p74EgnPrV4b43oP7Cdu2Usc9eXTC0cUAs3hsLuRErH/yVDA3z34CfZb+dSv9SEz9KMDtuJjXoaH+/9YPAoA4kqV5ngG6sq07oMYCQIHNjIXg8r3/A4PC0eSnGgJsyOXyyHwCYCdHhBTAARwzKLfr/a6cQiW4PBKbe1KTIlAFEK4QRCFtv+NRaCA5fyrYIED07PmZrLEh2LgJtC1eGUZKNjUV+gkE7Dw8EE6iIHqGirpQGFWKFjiIKBh0jo6AvsrKHpgi9U1GvNUQ8FhOxs4Ke9b6/Poe3+mK8JJYPEILXwxTixYTQi9KIKOqAiy0+laPk+cVGZ+GYmpyipe/w4cmt+BOAgYIusbv89vNs9Tb968fwYL6xgwcltAgw4Zn0hFc6HBiRIj9JFLMCA+jFY6jsoEMKXIkyZImT/+iTKlyJcuWLgMa8Uit0C+aKW7iNGFTZ5icVnz+BCpiT02hSYweNSpTz1JhO5VCRfo0aNQSU6laFVqUJ9esUpHeajrrKtaHXcuaPZsW7dq2Q79WdSuXbFK1c7/ANFhoGwq+JfyyBUxC8AjCdQevMGx4b9/Gdg2LUGwUMmWwQ/IWFNvTjGY9aTrb7QJ66Gh5n09zRg2mNFuLDlnL5QL7beoysw9DwVyxtm3Vq3n/9qK7H2QoxZ8cZ5J8yfIhzZ3jva1xOvVqw6tjz87wuvbu3stx/y5+/Efp5M+jj5l+PXtJ4cuxCmBAARQGCWw46JUFPxQHCUY4wN8SAigSAH37BeD/zRAEBIjPIAgq+AME840QH4UAWHhgDxMeSMADNhiARYaXmXeHAXUUEA4TEdQxIYoJEEBAAnUs0YAB/wFQAIwy0ijEhA2QoGOMMyIRAQIiIMCJkDwCEYENGp6YYzhRpuiDkwYyg8AODRxBpYp8lJgGJmfs0IUDODxAYwHtDKGjjiKkKcKaSDTAJpxq2tlkOw1UEWeOeRJy4JhDCTBoEmUGysZ/hmaC0ET2jZDAFlAIQGMCWDBw5BCsQAApAJeKkCkSCNwXQAI7gAqAqAsiYEAE+X2KqaZ8HOjppwvYKqkRGo4QwSC5TqqeQ8ByAcEbsYY6KxAcqopjqqsKkQCQABiJ/6yqygKRSo5EPottos1GiiuOt+5agg6hjqtrEO+NM2gciC6hQIR+1rlpNhDQC6gPDtDYBgD5InEhpACvK+gR77rbqDG8ajFCwvAaE2YaXkIhZJA7EsmEp0tmLISOgzygCsc9BoGANw6IjDHJC49AMQAus0wDHSXADCZFIz7RoA04NhghErb2zMSHDooQNBIEBvKg0T9cSQbOOPPQtAqOLIID1Da3l7XWtkm8tdfesfu12GMn0TXZZ08UNtprp6c222+L5zbcc2cnN913a2Q33ns3pDfff19kNuCDR+I34YdbJzjii3PNuOOvKf645K5NXjk5hltuRxwKL4555nDasP+FIl/yoEgdm0NMuOefD30kAyACYTocNqQ++OqZf6iIfQbIJ+ci0yrygCIIePjI5jYG0M49veN9u+UfNlAgIK1wyYmTQCqCfQB1yL75AgTwrgAg3tLtfOXQL5B8+q3ch0P6/8kOPQDd0/5yALgG0kDtbJs/ufwirO9TkHjf/Lb3rwBo73T1490MCtC0B5Uvcnv73zd6Vz1qIbCAdZBfgBTYKAaOoAYBgODc+ic5CgYwR79DkgHlBw4boM5+C+DSzrBwNxN+Lock0iEPZYHDHgKRHhIMIg9/SMQjdgSJSvTHEJdYOSM6MYhQjGIPp0hFHdKuUFrcIhe76MUvgjGMYhz/IxnLaMYzojGNalwjG9voxjdy0YpX/Jwc52i5OtpxcnjM4+NwgRI+XtGP7gCkEwXpgiYScmuGhJPOJoXIRGZtka/zxgKIRxtIInGRHbQMJukoBieEj5Puyc0TNCOWU5aSlExgzSJ5V7tHtoYPqZwlJVZJy1riUjSfBJABQyMKU97yFsEcwzCJacvoUKUNpwIAgfQDy9jI8pjSFOY0L6PKXMpmlyNYQCOh6QlgVtOa4VxXMck5zlVqkx4zOSQ71QmQQXrGnZt5Jz3rGU973jOf+sxNOvH5inkAtJ3z9KdXCBpLb+KGkwGV5z59aZF/PPOSA21oQSlaUVEmY6ETVahA/zd6UVGu65MnKc9LSmrSk6I0pSpdaUkoF4+IdvIgIX1F+mwR04u41BClsulNBZJTQ/gLHT3lx1L2WIKgynSo4PmpH5DqDJEoVSAhaY5RSeDUjgKAAhg4wAHOkVWu9pSGUSoBgwKxBaQl6EEM4J0brMq8jwpLFFdlqAiCAYBrAJIBDQNEFRQRrP0wAHwGGJIBIJC+I7XhSFyaFltJJ9GZiqJUCUqqXb0axM01aFoiIADyEjCI+zSwrSGEIWBfpyneGSuDynTYWw96SJjCs6559J6MsKRXGzxgUq5UYYQwEY4PFQAQ7QgfcJn5Vt+CNAywxWoUZls/4G4uAPppWaMA0f9b5gFXuCIgrgGRKwLvwjViejmEcxu1yduqL1L3U+GxaEDaADHAtNsd4fUwZCrWOjahccVpCexaiiOibkKc4yzvPMveAs7Ar4Cd0GBfVlj5JhaDmgWva4U43v6iAK9A3Nx9QnQCvW5BrDRScFnxcdYCOUCtbD0WW22g2cdibTckGEAwNNzDGPo0LBfGsAlszEMcv5SplztBMCwbVUMUdbl0le2RxyJkYTxjEURu8li0AVkZzxgFFOBqV6l8hyTvOMs9+K+X8fJk60y5Bz4u8zmxEWZY+GDNbKbmDjOTZh7Iec7GrDOW4dwDI+sZmzHmL48DXbgzr5O8PyCzocXJZ0//0DABvCKoXVeQ50Yzd7+SWOsgbJTU5v7g0pg2qJtDYZ9eLGBcSwZ1nEftaEf1IEaylvWK3KClT1caBYB2dWwHzYL0geSvP1CAZzOVpyiD5M68/sxUucEDYGdD2D7wUw1I6NFcr2DXy7aos3kw61mPoQ4NMHCKpktpIYh62zDWtAsIUIAGwLsB1vbF6YYmaVyjW929ZncLhrYIaftD2a3W96rF+wMDkMoBNtqfb/wMBG0THKEW9kEcuMkJBAC84UyOuHAQvdkr2Cjko1Q0x0XjcSQ9ABOhG3mhH17y5DJlCDPMuMZZDYR0bxvMP3hABBiOh0Jg29Ivd2i3e4DiApjb/w9AHwLOl63zHzDgAby7EJIF7gOIR/zpP6jUyg99CBoPvZyl9kEBCpTWPCD7F0HXctMx/YjnJPEHipCWz2u+8SC0vdFa50EBbPjNFaw9w2HXr8G9vVlws5zkQcB6zhGdvkpCg+a9+cTgBc3vEzze7F2vOuUr/+ort/vwtE58yz3PU9DzgOd1D3jnhTABLnt1y+reuwuOnvQgFK+Xmb47F/J+ZNq7IOpTn3TsYCVUqz/B91EFvgu4vl6Z57fgNucC4+fM/BWUfREpppNk/U7qwJs+vGM3uqn0tyJNvc7caY9G68MfMZBQVSJ958KchkJ8sIDf/esufA8UcH8j1EEb0P9Hue0b70EBo7na9aGAA5APAPqOqfyfQ+WfmnFV9VGZAmIe8Yye1yGf/nkU/5VO5JGemHlgAY5fCD6C5AVHB5Yg0b0W7iEeByreFyCgoWGgCWje83EeCyYfr91gCeSgCppZ+32B8t3UD5JVjAhAYY0gLIAdGBhhTCEhCchaG6zMz7XABP6ZD55cAT3CFX5ZFrag9BUdCuLH7ZVB2onhGCqXDcDdGWBEDMogD47hFI5ALxCAEK4gEXJBDQaaHWZBivFOA7Ie4JUB7LndycVBcOEDJMzh12khEPhhk9lhxTmJAiDAi+XBP0RiqP1hFyaAf0hXJjbhDELhJ+rYD9DQA9T/gPdh4QvcQRTyESDmCNLNEBoWIgt04tWh4qOFAiDMG7c5HBtWGEAg0gsFI0jt4qIhoghsWQWOwDN2mTNy2RLRohdgQvokowsaIDxY4B11oRdAgKRU26eZIjFe4x0uwcyU41OFBA8sY8mJRPyNig6G1CO4ojISIzcaYz3qoRWQTDvuXunFwyQWUTjCwQY64Ghto/iRID/I4uEAYoqkYCkSJDxEpOp0YYttntLBY0FM41dBYw4BogE8gBx6JCxWh0EiDiDWCUpuIjw+oUZk5NpMpAg+oiFOR02iTUni5A6qJE1mTkmepEKm5EdOxzf+jUsWZYxMQkLEI8EBYhBa5Dm2/+BU/uRRBqVGSGPsNaNIhmRXRuNXiiU1juRX9U04fpsfqKEa0NhbRiXb8KR7WJmveRtMvqIQxOXazGVOgmDtZWVMDsFeoo1SJpovAmZF+iVSliAtytoSNuTk6WUdqmWMWGFVrmFjdmEOgmEuAgFhng1LvgNWah8u2h1jVk5fAiXq3aVTPiUSgCbZqKZWsuYKzNwIwNuAFMitmeALzKTkzKZgIuYKtMp0cUkEBt9Jzo/PfKAPxObXGKZCIFoctFcNaGKbtBepqYFmpmK7ZdAdfucSeMjxDeaRYeIi9BwzUN2ewRoPJACM5IDuIYFylsD6PQITPOfXyN4XYMK0CMCZYP8QloQF/JUhC3BJAkRAAwRIgyHBHESmQ6Lm5MwmFYQBcg5kgbKA1HjYugSgAawehG6lhIKBDFSo5f1lCygAvCHdZaAINDwo4TknXOZne0QnD5CoCDliElgoGb6gnXXBjD4OhZ6BDQno59llkP1oTLXBG8QBke6odvZon+HnTZ2nDaSn1NBZexIaFADpeojmOKTjL3lBl6ZHcHrmkW7EmALnm6HpaI6pjMro35jpaWJomuYBmWJHjf4TQn6EH+CpdpQlWHrlWQZqoZLlV8JcCiiZCbQlHvwpFb1dbdqpo9pBlTJC7m0oFvGpmN6pmHznfzLAHGzJolJHmJpGp5qBkKL/ALFV0aaeKqWaAYmugK+0anduqR3Aaa7qapyewI1WTQ58KOOY6t/1g12pahJgQcMA0bC+ZrGuqmg16Rx05lC6KrHyQ6VZas9RzQ0cpK3aQ9KYIzk8qkZ6aySsw7/oS6K+wrjaTrUugbZgSPTxozCwK+Awa5HsgnT1ZjVMQyfd6xAsg3upH1Tt4z1mAz3+IiXJK4gW7LzGnDo0yiaEa8MK48T9IrjuK8UyrHKxqcY2Z526qcdmbD/6qMjyqMXeqsmqq1WQKlOw1MvCbMzK7My6hLvu6clqVMXC6P65Vs5iFM5e6M7ybLl2LIj6LD9mVNAerdECLY8uLTplxNNWWNIq/23VOq3VQqnQSi3RlmxiBC0AJMc/hK0LjG0LlC0LnK3X8uhysFLLjuzXwm3cZq3cfix5GmkpuS3d1u3bnqzerqzDzm3ftmnKsufdmpOJnl7hGm7i4m3UXlOWQq7iHm7kSm40CUfemq1xIIfmKsfmdq7nMsdqYK7KItnoku4mmu7pflnqqi6zta7YVNXrKgTrWtXwAYF9nGHRCEgP+AcvTVYPoNWBLA0LlFg+QEgLMMsq2G68ysf9JS+misjymkDyVogjXk0Irec9eMP1Xh4/1EzUtAiVqEwP2AiOjAwP/MjFDMm09oqmJMm2rO+sPknLoMiU1K8JXMmBiCoAcMl23f8v/s4v9m7o9waohkQPvBDwifIDowSrCQCon9RfC7gJjkBwupZAvZBABbtABOxJn+AJPRgMmTBwChAfq44wCd/hjIDKCVtFh3COcZHJcPIDsQRBpYhAt7gAp3gKDtdeqSwTDxNvq7xKLwCxHtRKuohLuKBwCdAqDeuEhigcsjixFRzI+1gpuNzwP7LssCBxEBhLpMgK8lLIDoexC0iLCFRLEaOAtriJtUCLEaNLuEzxGUzauWAxuSyxgt4wDsyx/YUKEy5hEmexDO/DwwCBvGQwjWDwCmyrDeCLIlswCfDLKqgAwbCAwPyHJcMxDM9OoRzMC9OxJE+KIS+xzlgpKbf/sPICiA58cgNvsUMkMAtYTA6Mbw9sTC1LsIGFDPwySQuYTNGkTPwCBJT8bywLqLTSzP8uMQmkijF3SJRgAn3EMsjuA/e2gCnzzO7yANBoc79h7PCuAFoZLzgz8X0y74VwL5Y2stVILwlgKTNHb/MCsJRhSKn0SzsPruySR+zqsw/Rbj9nE0BH0j8LNNQW9Hrw80E/JUErtJY2dNww9EN3r0RXR0JT9M9F9EVHqUZrh0VzNGdk9Ec/bMkBWUuGtHcMjei0Vgh6kCu/jUe/TeuoCuzInQGVtESedHfkzhUkwNQ94HcGz/DkHgy5GO8ozyIs7NnANNtAj/RYUPJIWAElq5AGzc79gI+BjI+95rR2oI/69E77VBD8tFAG0c8H3c/r4IP5Nc9WZwcKffUA3Vf8kLVNL9B6OdAivOjXLPXauDX1QHV9yTWQbFIMgRAzOPJax1Rf/zTwjDWQvJB01fUMLUKq3BBbizRpXHbdWPZl73VmN65nl+pmi3RngzbXlrZeiPZHk/ZpSyprR0Rqc/Rqu7YCzzZRwbZGy3Ztb7RuvzZvb8cb+vYsSEAIAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curve of metastatic well-differentiated neuroendocrine tumors of the digestive system. There is statistically significant difference in overall survival (A), disease-free survival (B), and progression-free survival (C) between grade 1 (G1) and grade 2 (G2) tumors based upon the highest Ki67 labeling index.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011; 35:853. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42734=[""].join("\n");
var outline_f41_46_42734=null;
var title_f41_46_42735="Bulging AOM";
var content_f41_46_42735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bulging acute otitis media",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Occasionally, bulging otitis media can mimic a cholesteatoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_46_42735=[""].join("\n");
var outline_f41_46_42735=null;
